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Rice is a staple food for millions of people,
predominantly in Asia, but lacks essential
nutritional components such as Vitamin A.
This is very important for over 180 million
children and women of child bearing age who
suffer from Vitamin A deficiency in Asia alone.
For this reason, an improvement was made
under an effort led by Profs. Ingo Potrykus and
Peter Beyer by inserting several genes into rice
to produce an improved product called
GoldenRice (on the trademark, see Note
on Trademark and Domain Names below).
Because GoldenRice has the potential to be
easily integrated into the farming systems of
the worlds poorer regions, the advent of
GoldenRice promises to go a long way
towards solving Asias Vitamin A deficiency
problem in an effective, inexpensive, and
sustainable way.
Objectives, Limitations and Definitions
As a result of the increasing complexity of the
intellectual property (IP) framework under
which the international agricultural
development community operates, the
Rockefeller Foundation funded an ISAAA
project to conduct a selective Freedom-To-
Operate (FTO) analysis of GoldenRice with
the objectives of:
a. reviewing the IP and Technical Property
(TP; or tangible property) components
associated with GoldenRice;
b. providing institutions interested in
distributing GoldenRice with the
information needed to develop strategic
options for handling the proprietary
science embedded in the product; and
c. developing possible alternative strategies
on how the IP/TP constraints could be
managed effectively.
Any FTO opinion is a risk management
opinion and its results vary on a country-by-
country basis. It is a dynamic opinion; never
a definitive answer. Hence the present
document serves as an analytical framework
that can serve as the basis of a legal FTO
review. While it contains information on
ownership and statutory protection issues, it
is not intended to be a final legal opinion.
In addition, this report is not aimed at
commenting on any institutions current IP/TP
strategy, but on providing relevant information
to make sound policy and strategy decisions.
Neither is this study intended to promulgate
any particular approach about how to
overcome the IP and TP challenges while
dealing with the proprietary science of
agriculture and plant breeding.
Proprietary Property, or proprietary science,
as used throughout this document, is
comprised of:
• IP or Intellectual Property, which has been
taken to mean, without limitation,
intellectual property rights, including
patent rights, plant variety protection
certificates, unpublished patent
applications, and any inventions,
improvements, and/or discoveries that
may or may not be legally protectable,
including all know-how, trade secrets,
research plans and priorities, research
results and related reports, statistical
models and computer programs and
related reports, and market interests and
product ideas; and
• TP or Technical Property, which has been
taken to mean, without limitation, tangible
property such as computer software,
germplasm and the biological materials




Results of the Deconstruction of
GoldenRiceTM
Under the product deconstruction process of
GoldenRice, we reviewed plant/seed
source; gene constructs (TP and IP) of cloning
vectors pBin19hpc, pZPsC and pZLcyH;
transformation, plant regeneration, and other
techniques; and DNA amplification
technologies.
Technical Property
At least fifteen TP components went into the
three different genetic constructs; many of
which were acquired by ETH-Zürich under
Material Transfer Agreements or by use
licenses. Some of this complexity stems from
the product being a multi-transformant, in
which three genes/enzymes (phytoene
synthase, phytoene desaturase, and lycopene
cyclase) were introduced in the carotenoid
biosynthetic pathway (Figure 1 shows the flow
chart of the elements that went into one of the
three constructs or plasmids). This required
three transformation vectors and the
application and use of many other processes
and components. For reasons related to the
confidentiality embedded in these
agreements, we are not providing details of
these agreements nor our interpretation of
them in this published version of the FTO.
Determining what entity has the right to grant
licenses or sub-licenses is a relatively tedious
process, one which continually evolves as
companies re-structure, sell or assign patents,
or grant licenses with or without the right to
sub-license. Hence at this stage we only
identified the patents according to the original
assignee and have not determined which
entity would have to be approached for
licensing the various components.
Intellectual Property
Depending on the country where the current
form of GoldenRice would be used we
identified between zero and 44 patents which
applied to the product. In the USA and most
countries of the European Union, around 40
patents apply. In the 10 top rice producing
countries, many fewer patents apply, namely:
China (11), India (5), Indonesia (6),
Bangladesh (0), Vietnam (9), Thailand (0),
Myanmar (0), Japan (21), the Philippines (1)
and Brazil (10). Similarly, in the top ten rice
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importing countries, relatively few patents
apply: Iran (0), Brazil (10), Nigeria (0), the
Philippines (1), Iraq (0), Saudi Arabia (0),
Malaysia (0), South Africa (5), Japan  (21) and
Côte dIvoire (10).
Recognizing that patent claims may be
granted for different kinds of inventions,
claims may be worded to cover products per
se, products-by- process, uses, or processes.
Whereas the first three types of claims
generally extend to the products that embed
the new discoveries, process claims or
claims for the claimed technical procedures
do not extend to the products that are
produced by the claimed processes.  What is
of great importance for process claims is the
country in which the process is applied. If the
product is made in a country where those
process claims have not been issued, then
a license for such claimed processes are not
required.
A total of 26 of the approximately 70 patents
identified in this study contain primarily
process claims thus reducing somewhat the
number of applicable patents which could
inhibit FTO in a given country. A detailed
analysis on a country-by-country basis may
reduce the complexity of the IP landscape.
Discussion on Alternative IP/TP
Management Strategies
Transfer and use of GoldenRice, depending
on the country in which it is to be deployed,
would, at a minimum, require agreements from
a dozen or so entities (public and private) for
the TP transfer and use. In addition, again
depending on the country of use, between
zero and 40 licenses for IP rights would be
required, from a dozen or so entities. In total,
negotiations with 12 to 20 entities might be
required, again depending on the country of
release. Noteworthy is that if a regional or
international organization, such as the
International Rice Research Institute (IRRI),
wishes to obtain FTO, say for national use in
all developing countries in Asia, licenses for
around 30-40 patents would need to be
obtained (in addition to the resolution of TP).
All in all, the widespread release of the current
version of GoldenRice will require
significant licensing activity if it is to
legitimately become available to the world,
either commercially or for humanitarian
purposes.
We identify and discuss the advantages and
disadvantages of six alternative strategies on
how to gain FTO for GoldenRice, namely:
1. Invent around current patents:
Research alternative ways to develop pro-
Vitamin A rice, generating new inventions.
This option, which is a science and
research based approach, leads to less
reliance on other institutions patents but
is likely to be very costly and time
consuming (if at all feasible). It would
arguably not constitute a wise use of
development funds.
2. Re-design constructs:
Re-design each construct to reduce
number of applicable patents, whenever
possible synthesize own genes to reduce
reliance on TP of others.
This strategy, which is a product
development based approach, is a likely
one as it may be necessary for scientific
reasons to re-design the product. It is an
effective way to reduce other institutions
IP and particularly efficient if an FTO
analysis is done prior to initiation of the
research. This approach would almost
certainly be the approach favored by any
company as the TP issues are potentially
the most difficult ones to resolve.
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3. IP/TP owners to relinquish claims:
All FTO issues for all GoldenRice related
activities, commercial or otherwise, are
eliminated through public (or private)
statements and related activities by the
certified owners/assignees of each set of
IP/TP rights for making, having made,
using, having used, importing, exporting,
selling, and having sold all GoldenRice
plants, plant parts, and all related products
and processes. This humanitarian strategy
focuses on public perception.
Some companies (e.g. Zeneca and
Monsanto) already publicly declared that
they will make their technologies available
for GoldenRice. This will greatly simplify
licensing negotiations although a royalty-
free license may still need to be negotiated,
at least for liability/indemnity reasons.
4. Ignore all IP and TP:
All FTO issues for all GoldenRice related
activities, commercial or otherwise, are
ignored, and research and product
development as well as plans for general
distribution proceed.
This approach is a strategy that certainly
has the lowest near-term costs but may lead
to long terms costs, especially if a lawsuit
ensues, and may lead to the longest delay
in product dissemination.
5. Seek Licenses for all IP and TP:
All FTO issues are resolved by the process
of any party (individually or through
consortia) acquiring an appropriate
(commercial or other) license from the
certified owners/assignees for each set of
IP/TP rights for the GoldenRice related
activities that are of interest to the licensee.
This license may be commercial in nature
(a grant to make, have made, use, have
used, import, export, sell, or have sold all
GoldenRice plants and plant parts and
all related products and processes) or a
more restrictive one as the licensee and
licensor mutually determine to be
required.
This licensing approach is complex and
costly, but may lead to stronger public-
private relationships whereby
corporations are also willing to transfer
know-how and future biotechnology
inventions. It is also the safest route and
ensures good relations with IP owners (be
they from the public or private sectors).
6. Mix of all Options (1 to 5):
While research and development plans are
made to optimize the product, re-design
of constructs and acquisition on TP is
planned to minimize IP and TP conflicts
(OPTION 2); selected FTO issues are
removed through public (or private)
rescinding of rights by selected holders of
certain IP/TP rights (OPTION 3);  this
moral high ground is used to leverage
additional rights holders to either rescind
their claims (OPTION 3) or to reduce their
demands within the context of license
negotiations (OPTION 5). In the end all
remaining unrescinded IP/TP rights can be
either licensed (OPTION 5) or ignored
(OPTION 4).
This strategy is again complex from the
perspective of IP/TP management but
seems to be the most pragmatic and
realistic. It capitalizes on the upsides of
most of the other options while reducing
the risks of future complications.
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Discussion on Risk Management
Strategies
Developing a sound IP management strategy
is, in many ways, primarily a matter of risk
management. No one ever definitively knows
who has rights to do what with all IP, because
new patents are continually being issued,
older patents expire and patent-related court
settlements take place around the world. All
that any organization can do is try to comply
with the FTO opinions that they commission,
establish protocols to defend (or proactively
fight) themselves, and seek whatever licenses
they believe that they need to reach their
goals.
For international institutions, licensing issues
are further clouded because their donors and
clients are from many different nations.
Thereby the statutory protection laws required
for full FTO are as varied as their client list.
This leaves such institutions, particularly the
centers of the Consultative Group on
International Agricultural Research (CGIAR)
with the challenge as to whether or not to
distribute improved germplasm with full FTO
or to pass this responsibility for obtaining FTO
along with their improved germplasm, on to
the client nation with a caveat regarding these
matters.
For the present FTO, we also had to make
strategic decisions on how wide a net to cast
in terms of listing certain patents where it is
not entirely clear whether or not they apply to
GoldenRice, and whether or not to include
patent applications or only issued patents. We
opted to cast a wide net so as to provide those
institutions who wish to further develop and
distribute GoldenRice with a broad base of
information to make sound risk management
decisions. ISAAA, through the Global IP/TT
Initiative, can be assisting institutions in
developing appropriate and pragmatic IP
management options or strategies.
Conclusions
Regardless of which option discussed above
or which scenario is chosen, there are a series
of tasks that should be completed in order to
adequately manage the IP/TP. These are:
1. Complete and regularly update the present
FTO analysis, preferably on a country-by-
country basis.
2. Develop a scientific strategic plan (who
manages, what is to be done, which
biotech and germplasm components are
to be used, where is the research to be
done, who is to do the research, what are
the timelines for completion) for finalizing
the current scientific initiative.
3. Draft and negotiate a strategic plan for
distribution (who manages, what must be
licensed, list of licensors/licensees,
acceptable terms, timelines) of the finished
product(s).
4. Complete a cost/benefit analysis for the
preferred options.
It will be for the developing countries, which
wish to benefit from GoldenRice and for the
organizations whose mandate is to assist these
countries to make choices on the best options
to follow. The dominating consideration must
be the impact of GoldenRice on the health
and well being of rice producing and
consuming populations. These and related
factors will condition the speed and
configuration of the eventual broad release of
GoldenRice.
National Agricultural Research Services, once
they obtain access to GoldenRice, may still
wish to conduct their own FTO review in order
to confirm which IP issues and TP issues are
covered in their country. This is particularly
true if the recipient country foresees an export
market for its GoldenRice. Additionally, any
country to which they export their




Because a preliminary FTO analysis such as
this one and a related version done by a patent
attorney is dynamic, it is essential that a
strategic plan be developed by any entity
wishing to develop and disseminate the
product in light of an extensive cost/benefit
analysis and list of alternative strategies.
Resolving the IP and TP issues still provides a
formidable challenge to the ultimate release
of GoldenRice. We hope that the systematic
review, presentation and discussion of the IP
and TP situation will lead to sound planning
and eventual resolution of the issues. In this
way, GoldenRice will deliver its benefits to
both resource-poor farmers and consumers in
developing countries and to commercial
farmers and related entities. It can become a
clear example of how the benefits of
genetically modified products can be
extended to both developing and developed
countries. Sound planning and resolution of
the IP/TT issues will contribute to a timely
release of this and future essential products
for the benefit of all people.
Note on Trademark and Domain Names
ISAAA has filed for a United States Trademark
for the words GoldenRice and Golden
Rice, and for the logo as provided on the
cover of this report, and registered the domain
names www.Golden-Rice.com and
www.GoldenRice.org.
These protections have been sought to ensure
that the name GoldenRice remains in the
public domain for the benefit of resource-poor
farmers. ISAAA will be pleased to transfer the
trademark rights and domain names, at no
cost, to a philanthropic, academic, or
international development organization who
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11. Background and Introduction
1.1 Rice Consumption and Vitamin A
Deficiency in Asia
Rice is one of the worlds oldest cereal crop,
and together with wheat and corn, it is one of
the core staple cereals worldwide today. Nearly
94% of all the worlds rice is grown and
consumed on the Asian continent, where it is
by far the most important food crop.
While rice is a good source of calories, it lacks
essential nutritional components. In particular,
rice contains neither Vitamin A nor beta-
carotene, which humans can convert into
Vitamin A.
Note that the rice endosperm, however, does
contain a beta-carotene precursor compound
but that the plant is unable to convert the
precursor into beta-carotene itself. As a
consequence, it is theoretically possible that
some landraces of rice may contain beta-
carotene.
For children and women of child bearing age,
Vitamin A is absolutely essential. Worldwide,
nearly 134 million children are at risk for
diseases related to Vitamin A deficiency. Some
3.1 million preschool age children suffer from
eye damage, and nearly 2 million children
under 5 years of age die each year from
diseases linked to persistent Vitamin A
deficiency. In Southeast Asia alone, 5 million
children become at least partially blind every
year. In the past, attempts to solve this problem
by fortifying rice with Vitamin A have been
stymied because of the costs involved and a
general lack of infrastructure for efficient
distribution in many developing countries. But
thanks to the recent efforts of scientists working
on this problem, Vitamin A producing beta-
carotene can now be genetically added to
rice. This invention has the potential to
alleviate the suffering of many millions of
people, especially those who are too poor to
diversify their diets with green vegetables.
The improved product is called
GoldenRice because of the slightly yellow
endosperm resulting from the added beta-
carotene. In its current formulation,
GoldenRice could supply more than 10%
of an adults daily Vitamin A requirement. As
the technology is further developed and
enhanced, GoldenRice will be able to
provide 100% of the daily Vitamin A
requirements for adults living in poor regions
with high per capita rice intake (110-180 kg
per year). Because GoldenRice can easily
be integrated into the farming systems of the
poor in these regions, this new variety has the
potential to make the greatest impact where it
is most needed. The advent of GoldenRice
promises to solve Asias vitamin A deficiency
problem in an effective, inexpensive, and
sustainable way.
1.2 Biotechnology Research and the
Development of “pro-Vitamin A
Rice” (GoldenRiceTM)
Focusing their research and development
efforts either on model plants, such as tobacco
or Arabidopsis, or on commercially important
crops such as maize, soybeans, and cotton,
biotechnology companies at first had no
commercial interest in rice. Instead, rice
research was pursued by the public sector. A
major international rice biotechnology effort
in the early 1980s was initially funded by the
Rockefeller Foundation, which has since
invested well over US $110 million in rice
biotechnology research and capacity
building. This has been a most successful
scientific investment that trained a large
number of scientists from developing countries
and led to enabling the transformation of rice.
One of these projects, led by Professor Ingo
Potrykus, undertook to determine whether
beta-carotene could be added to rice through
transformation. A collaborative effort between
2the Swiss Federal Institute of Technology (ETH-
Zurich) and the University of Freiburg,
Germany, allowed scientists to begin their
work in the early 1990s. The project received
funding from ETH-Zurich itself, the no longer
existing European Community Biotechnology
Program, and the Rockefeller Foundation.
The research team engineered a japonica
variety of rice with the three genes (psy, crt1,
and lyC) necessary for the rice grain to produce
and store beta-carotene. Two simultaneous
transformations were necessary, and this
inevitably led to complex plasmid constructs.
In fact, the Vitamin A package included two
genes from daffodil and a third from a
bacterium in order to complete the beta-
carotene pathway in rice.
The research group worked with japonica rice,
which is mainly grown in the temperate zones
of East Asia, because the transformation
systems for it were well established at the time
the original work was done. In the future, the
successful transformation events in japonica
rice may be crossed into indica rice either by
IRRI or by NARS directly. IRRI is also planning
to introduce the genes for beta-carotene
synthesis into elite tropical indica rice by
transformation and evaluation before release
to NARS. Indica is prevalent in the less
favorable ecosystems where many of Asias
poorest people reside.
1.3 The Institutional Context of
GoldenRiceTM
Since its inception exactly 40 years ago, the
International Rice Research Institute (IRRI) has
made incredible strides in meeting the food
needs of poor people in developing countries,
particularly in Asia. Its main strength has been
its ability to freely receive and distribute
improved rice germplasm and related
information. In fact, this free flow of material
and related information has been used by
many of IRRIs funding sources to measure
performance. Given this success, IRRI
management and scientists understandably
place a high value on the free exchange of
information and material.
By 1990, IRRI launched its own
biotechnology unit (although it had practiced
tissue culture, isozyme screening, anther
culture, and embryo rescue for quite some
time). From its inception, IRRI biotechnology
researchers sought assistance in the form of
materials and related information from outside
sources. Nearly all of this assistance included
proprietary material comprising Intellectual
Property (IP) and Technical Property (TP) rights.
When such proprietary material was
transferred to IRRI, it was often under restrictive
conditions such as material transfer
agreements and other sorts of licensing
arrangements. Receipt of such protected
materials and related information induced IRRI
to institute certain restrictions on
confidentiality, review its publication
procedures, modify its processes for the
release of IRRI-held germplasm, and seek a
clearer path forward regarding IRRIs use of
the progeny of transferred materials and related
information for later release to its clients.
With the rapid expansion of plant
biotechnology, particularly since the early-
1990s, it has become apparent that IRRIs
open approach is unlikely to be sustained. For
IRRI to ensure that its clients will continue to
have access to the best available germplasm,
some form of intellectual property protection
system may have to be implemented.
Accordingly, its historically open and free
system of germplasm and information
exchange might have to be modified over
time, particularly for certain projects and for
certain genetic materials produced under
those projects. This is partly because the
private sectors large R&D investments led to
many patents in plant biotechnology
including ricethat are no longer freely
available to the international development
community. In addition, many public
3universities and research institutes are, by
necessity, becoming more and more secretive
about their research projects and are
increasingly seeking intellectual property
protection for their own discoveries.
In the mid-1990s, the Consultative Group on
International Agricultural Research (CGIAR)
also began to study the effect of biotechnology
on its plant operations. It set-up two panels.
The first focused on how the Centers of the
CGIAR could fulfill their international mandate
from the scientific and technical perspective.
The second focused on the implications of the
increasingly proprietary nature of
biotechnology. As a result of these
deliberations, most of the CGIAR Centers
commissioned an IP audit from 1999-early
2000. These audits generally reported on the
overall handling of IP by the Centers. To chart
a path forward, the Rockefeller Foundation
commissioned ISAAA to conduct a
preliminary FTO review of the GoldenRice
project for IRRI.
2. Objectives, Limitations and Methodology of the Freedom-to- Operate Review
2.1 Objectives and Purpose
As a result of the increasing complexity of the
IP framework under which IRRI, the research
collaborators, and the NARS operate, the
Rockefeller Foundation commissioned ISAAA
for IRRI, to conduct a selective FTO analysis
of the transgenic product containing beta-
carotene produced by ETH-Zurich. The
impetus for the FTO analysis also stems from
significant changes in the statutory protection
environment in the last decade, particularly
in regards to the World Trade Organizations
Trade Related Intellectual Property agreement
(WTO/TRIPs). IRRI is now seeking to ensure
open access to the services and improved
products that emanate from its research
programs and those of its collaborators.
The objective of the Freedom-To-Operate
(FTO) review is to provide IRRI with the
information it needs to develop strategic
options for handling the proprietary science
embedded in the Vitamin-A rice
(GoldenRice). This also includes
information to enable IRRI the development
of strategic options on how best to release
such improved products.
IRRIs efforts to reach its goal will be most
effective if they are based on all the
information available about the ownership of
the proprietary and intellectual property that
IRRI uses in each step of the development
process (see Section 3.1 below). The primary
purpose of an FTO review is to identify the
owners of such property. Accordingly, this
review provides IRRI and the Rockefeller
Foundation with a worldwide inventory of
patents that apply to specific products and
processes that were used in the production of
GoldenRice. It also discusses the possible
significance of these findings in regards to the
proprietary technologies that have been used.
In preparing this review, ISAAA has consulted
with a retained Attorney specializing in these
matters.
The present preliminary FTO is aimed at
providing IRRI and any other organization
interested in GoldenRice with a picture of
the current situation in terms of ownership
issues around the particular rice product. This
will allow any organization to decide, based
on rational information, what strategy to
follow. Thus the report is not aimed at
commenting on IRRIs current strategy, nor on
recommending a particular strategy, but on
providing relevant information to make sound
policy and strategy decisions.
42.2 Limitations
Given the ever-changing biotechnology and
IP environment in which every plant breeding
and biotechnology institution operates today,
virtually no transfer of germplasm or research
is without some degree of risk. As transgenic
strategies begin to dominate crop
improvement practices, both the risks and
rewards of transferring and releasing products
by national programs can be expected to rise.
An FTO opinion is a risk management
opinion. It is a document written by an attorney
(or for a preliminary FTO, written by paralegal
staff and reviewed by an attorney) and is
prepared for the purpose of guiding an
organization through or around perceived risk
(see Section 3 for further details on FTO
reviews/opinions). These include aspects
related to technical property (such as
constructs, plasmids, vectors) and intellectual
property (patents on products and processes)
that may influence an organizations freedom
to enter into the product development phase,
or distribute and use the materials derived
therefrom. When an FTO is broadened to
cover biosafety and other regulatory aspects
and obligations, it becomes a Product
Clearance (PC) profile.
It should be noted that the FTO opinion,
including the information presented in this
report:
• varies on a country-by-country basis
because most statutory protection is
founded in national law, and patents are
issued by national governments;
• is dynamic because patent status is
dynamic (new patents are issued or expire
daily, sold or licensed, disputed or
rendered invalid by courtstherefore
ownership changes, and the impact of
specific claims are constantly  changing);
and
• is always an opinion and never a definitive
answer.
As a consequence, the present paperas
indeed any review of FTOmust be regularly
reviewed, updated, and specifically adapted
to the country that will receive the material.
Similarly, the opinions presented herein are
for the sole purpose of assisting any
organization that wishes to develop and
distribute GoldenRice in determining its
strategy for in-licensing, out-licensing, and
material transfer, so that the organizations
behavior can be justified should a dispute
arise.
2.3 Methodology
Conducting this IP/TP Audit of GoldenRice
required a methodical series of steps. The
deconstruction of this product was systematic,
utilizing any and all information that could
shed light on the products components and
assembly. In sum, these were:
• Scrutiny of the original review article on
GoldenRice (Ye et al. 2000) and several
others.
• Discovery of all related and relevant
references by searching scientific
databases (CAB, BIOSIS, AGRICOLA).
• Careful examination of all related
information, including, where available
but not limited to, additional articles,
project proposals and grant  funding
agreements.
• Review of employment agreements.
• Examination and construction of the origin
and movement of technical property
(construction of flow-diagrams of
plasmids).
• Patent searches on ISAAAs proprietary
patent database and others, such as
Micropatent, USPTO, and IBM.
• Patent examination, particularly in regards
to claims.
• Construction of an IP/TP spreadsheet.
5• Simultaneous examination of all
components (i.e., IP/TP scientific
commodity), in order to assess the IP/TP
landscape.
• Report preparation, including discussion
on implications and possible options.
3. Biotechnology Product Management: The Role of Freedom-to-Operate
Reviews
3.1 Why Biotechnology Product
Management is Important
Reduced to its simplest form, in regards to
germplasm development there are only three
goal-directed steps by any plant breeding
organization, be it a NARS or a center of the
CGIAR, or a private company. Beginning with
the goalor the end productand moving
backward, these steps are:
• Final Step: Enable the release of
improved germplasm and related
information (either directly or through third
parties);
• Middle Step: Develop and produce
improved germplasm (intermediary or
finished) and related information through
scientific and technical value added
research, processes,
and discoveries; and
• Initial Step: Conserve, use, and distribute
germplasm and information, and obtain
information and/or germplasm, and obtain
or generate and develop the
biotechnology tools and components
needed to produce improved (including
transgenic) varieties.
More specifically for the Centers of the CGIAR,
to reach their goal, the centers strategy has
long been to work through various
partnerships to include a wider range of
collaborators and expertise. One set of
collaborators is downstream to ensure the
delivery of the Centers improved germplasm
to farmers through national programs. The
other set of upstream collaborators
strengthens the CGIAR Centers access to new
technologies, particularly biotechnology,
through various types of collaborative projects.
With time, these may increasingly include the
private sector.
There are several reasons to form various types
of partnerships with the private sector.
Principal among them is that the private sector
owns the majority of the pieces required for
any of the biotechnological applications that
hold so much promise for farmers, particularly
in the poorer areas of the developing world.
This is irrespective of Monsantos
announcement on April 3, 2000 that it will
make its rice genomics information freely
available to scientists. Relationships, however,
are built on legal arrangements founded on
mutual trust, and are nurtured and sustained
by the ability of each partner to understand
and supply the needs of the other partner.
Through the vehicle of agreements,
organizations define how they will interact,
and all such legal arrangements should be
unambiguous to avoid creating confusion and
ill will. Furthermore, for any organization to
be able to collaborate effectively with private
sector organizations, a good understanding of
the other sides needs and wants are important.
Only then can costs (monetary or non-
monetary) be estimated realistically and the
relative value of different alliances compared.
Thus, proprietary science rights management
issues are both about legal documents and
about building, strengthening, and
maintaining relationships. In sum, mutual trust
and understanding is needed to establish
sound legal arrangements, and legal
arrangements are needed to maintain trust.
63.2 What is a Freedom-to-Operate
Review and How is it Done ?
Much of the material in this section is drawn
from ISAAAs Intellectual Property
VirtualWorkshop Module,1  a web-based
training course with interactive evaluation and
laboratory exercises, glossaries, and template
agreements prepared by Dr. Stanley Kowalski
of ISAAA.
An FTO opinion refers to the legal opinion
regarding IP and TP. It should be conducted
as early as possible, even during the
conceptualization of a research project. This
approach makes it possible to decide in
advance which components, technologies,
and processes are best incorporated into the
product under development and thereby how
to reduce or avoid certain IP and TP issues.
To reach FTO opinion, the first step is to create
a Product Clearance (PC) profile. The PC
process systematically dissects both the
products scientific (acquisition of materials,
agreements, and laboratory techniques) and
business aspects (biosafety, varietal
registration, and distribution status). This
dissection is referred to as the
deconstruction of the product.
Deconstruction can take place when the
product is in the planning stage, when
development is underway, or when the
product is ready for distribution. But it is in
any organizations strategic best interest to
conduct a deconstruction at the earliest
possible phase in product development.
To conduct a deconstruction four key
questions have to be asked:
• What are the methods and procedures
that went into product development?
• What are the components of the product?
• What are the ingredients that constitute
each component?
• What are the IP and TP rights that may be
attached to these components and their
ingredients?
As new patents are issued or old ones expire,
as companies merge, and as public and
private sector organizations alike license or
assign certain rights to patents, the IP
landscape for any product evolves and
changes. Hence FTOs and PCs are developed
in a fluid, dynamic environment. The timely
initial PC determination and development of
FTO opinions are only steps in an ongoing
process that must be regularly updated. With
50-100 new plant biotechnology patents and
applications issued each month, as well as
numerous patents expiring, regular monitoring
and updating of PC files is essential.
The preparation and content of a product
profile can be easily illustrated using a loaf of
bread as an example: We can list the generic
ingredients used to make the bread (flour,
liquid, yeast, salt, and shortening) and the
generic technologies (sifting, mixing,
kneading, baking, slicing, and packaging)
used to assemble the ingredients and to
manufacture the bread. Each ingredient in the
profile can be specified more precisely. We
can indicate whether the flour is soy, corn, or
wheat, whether a wheat flour is whole wheat,
or enriched, bleached, and whether the liquid
is water, milk, or beer. Similarly, the
technologies can be defined in greater detail.
The completed product profile then represents
the entirety of the breads construction
(Duesing, 1997).
1 The entire Intellectual Property VirtualWorkshop , prepared by a number of experts from around the world, is accessible
upon subscription. One module, entitled How to draft a Confidentiality Agreement? can be viewed by visiting www.isaaa.org/
ip.html.
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be considerably more complex than a loaf of
bread, and will require a much more
sophisticated repertoire of knowledge, skills,
and resources. Above all, however, clear,
organized records detailing all of the
procedures, components, material transfers,
and agreements that went into the product
undergoing deconstruction must be in place.
In this context, a laboratory notebook is a
critical management tool for later reference
during the FTO process.
In addition to uncovering useful scientific
terminology (see also Section 3.2.3 below), a
search of the scientific databases will also yield
publication dates, authors, and affiliated
institutions pertaining to key scientific papers.
All of these can also be utilized in a patent
search. Useful scientific databases for
searching agricultural biotechnology and
related topics are:
• BIOSIS - http://www.biosis.org/
• CAB International - http://www.cabi.org/
• AGRICOLA - http://www.nalusda.gov/
ag98/
• Current Contents Connect' - http://
www.isinet.com/
In order to determine relevant patents
associated with the product under
deconstruction, the next step is to search the
patent databases. These databases could
include, among others:
• IBM Intellectual Property Network -
http://www.patents.ibm.com/ibm.html
• MicroPatent' - http://
www.micropat.com/
• European Patent Office - http://
ep.espacenet.com/
• US Patent and Trademark Office - http://
www.uspto.gov/patft/index.html
Most major companies have their own
attorneys, and scientists review each and
every biotech patent issued and annotate them
in their own proprietary databases2 . Since
each database has distinctive, salient features,
it is a good strategy to combine and integrate
different databases in a comprehensive search,
since this combination will produce a broad
and thorough result. It also serves to cast the
widest net possible for identifying all possible
relevant patents.
Searching out TP involves a different strategy.
To discover who obtained what from where,
when, and how is the heart of the TP search.
Obviously, databases are not available for this.
Extensive networking is the way to proceed
with all scientists who worked on the product.
The objective is to discover, uncover, and
obtain copies of any and all material transfer,
licensing or notice to purchaser agreements,
as well as grant proposals, funding
agreements, employment agreements, and
confidentiality agreements.
2 ISAAA has obtained such a truncated database from a donor for ISAAA use. That database was used for this present
FTO, among others.
4. Deconstruction of the GoldenRice™ Product
4.1 Overview
The product deconstruction of GoldenRiceTM
was complex. It yielded over fifteen tangible
property components and approximately
seventy patents and related IP that seem to
have been integral to the products
development. Some of this complexity stems
from the product being a multi-transformant,
in which three genes/enzymes (phytoene
synthase, phytoene desaturase, and lycopene
cyclase) were introduced in the carotenoid
biosynthetic pathway. This required three
transformation vectors (pBin19hpc, pZPsc
and pZLcyH) along with the application and
8use of many other processes and components
(e.g., Agrobacterium-mediated co-
transformation).
Table 1 (Product Clearance Profile) presents a
summary of the relevant patents that were
identified and that are potentially applicable
to the GoldenRice product. It lists these
patents according to the original assignee.
Note that although a company may have
acquired another company by purchase or
some other manner (e.g., DuPonts purchase
of Pioneer Hi-Bred International Inc. in 1999),
the ownership of certain IP and TP may be
retained by the acquired company. In this case,
from an FTO point of view, licenses may have
to be obtained from Pioneer rather than
DuPont. Determining what entity has the right
to grant licenses is a relatively tedious process,
one which continually evolves as companies
re-structure, sell or assign patents, or grant
licenses with or without the right to sub-license.
The present study did not determine which
entity would have to be approached for
licensing certain components.
Table 1: Product Clearance Profile: Possible Required Licenses and/or Agreements for GoldenRice
Name of Institution Possible Applicable Patents
1. AMOCO US5545816, EP0471056, US5530189,
WO9113078, US5530188, US5656472
2. Bio-Rad Inc. US5186800
3. Biotechnica WO8603516
4. Calgene WO9907867, WO9806862
5. Centra National de la R.S.K. WO9636717
6. Cetus WO8504899, US4965188, EP0258017
7. Columbia Univ. of New York US4399216, US4634665, WO8303259
8. DuPont WO9955889, WO995588, WO9955887
9. Eli Lilly US5668298
10. Hoffman-La-Roche US4683202, EP0509612, EP0502588, US4889818
11. ICI, Ltd. WO9109128,
12. Japan Tobacco EP0927765, US5591616, EP0604662, EP0672752,
US5731179, EP0687730, WO9516031
13. Kirin Brewery JP3058786, US5429939, US5589581, EP0393690, US5350688
14. Life Technologies
15. Max Planck Gesell. EP0265556, EP0270822, EP0257472
16. Monsanto US5352605, US5858742, WO8402913
17. National Foods RI JP63091085
18. N.R.C. Canada WO9419930
19. Novartis AG
20. Nederlandse O.V.T. EP0765397, WO9535389
21. Phytogen US4536475
22. Plant Genetic Systems US5717084, US5778925, WO8603776, WO9209696
23. Promega US4766072
23. Rhone-Poulenc Agro USRE36449, WO9967357
24. Rutgers University
25. Stanford University US4237224
26. Stratagene US5128256, US5188957, US5286636, EP0286200, WO880508
27. University of  Maryland WO9963055
28. University of California US4407956, WO9916890
29. Washington State University
30. Yissum R.D.C. US5792903, EP0820221, WO9628014
31. Zeneca Corp. US5750865, EP0699765A1
Note that these are the names of the owners or assignees of the rights under the relevant patents. Because of possible subsequent
licensing or assignment, these are not necessarily the current entities to approach for licenses.
9Table 2 lists the tangible property received by
ETH-Zurich, including the apparatuses used
in the transformation. Some components were
obtained under research-only licenses or
research only material transfer agreements
(MTA), whereas others included use licenses.
For reasons related to maintaining a certain
level of confidentiality embedded in these
agreements, we are not providing details of
these agreements nor our interpretation of
them in this published version of the FTO.
It should be noted that the absence of an MTA
does not necessarily mean that no restrictions
apply to the further use or transfer of a
particular piece of tangible property. In fact,
the absence of an MTA or license may signal
the need for greater caution when proceeding
with the release of GoldenRice.
4.2 Movement of Tangible Property
The development of the product also led to a
number of material transfers. Figures 1, 2, and
3 present the flow of material for each plasmid
that went into GoldenRice.
As with most transformated plant products, a
number of events were produced with each
of different constructs (see Table 1, 2 and 3).
This present analysis is based on ISAAAs
review of published research papers and
various interviews.
4.3 Intellectual Property Analysis:
Deconstruction of the
Components
The detailed analysis of the intellectual and
tangible property of each component used to
produce GoldenRice led to the Product
Clearance Spreadsheet (Table 3); the summary
of which had been given as the PC profile (see
Table 1). The comprehensive analysis of the
deconstruction process is presented under
four major categories:
1. Plant/seed source
2. Gene constructs (cloning vectors):
• The plant transformation vector,
pBin19hpc
• The plant transformation vector, pZPsc
• The plant transformation vector,
pZLcyH
3. Transformation, plant regeneration, and
other techniques
4. DNA amplification.
Table 2: MTAs, Licenses, Documents and Agreements Relevant to GoldenRiceTM
Product Component Source of component
1. Rice germplasm transformed with gene construct(s) Taipei 309, obtained from IRRI
2. PGEM4 Promega
3. PbluescriptKS Stratagene
4. PCIB900 Ciba-Geigy Limited (now Novartis Seeds AG)
5. Camv35S Promoter (component of pCIB900) Monsanto
6. Camv35S Terminator (component of pCIB900) Monsanto
7. AphIV gene: hygromycin Phosphotransferase Ciba-Geigy Limited (now Novartis Seeds AG)
    (component of pCIB900)
8. PKSP-1 Thomas Okita, Washington State University
9. GT1 Promoter: glutelin storage protein Thomas Okita, Washington State University
    (component of pKSP-1)
10. PUCET4 N. Misawa, Kirin Brewery Co., Ltd.
11. Pea Rubisco transit peptide (component of pUCET4) N. Misawa, Kirin Brewery Co., Ltd
12. CrtI gene: phytoene desaturase (component of pUCET4) N. Misawa, Kirin Brewery Co., Ltd
13. PPZP100 Pal Maliga, Rutgers University
14. pYPIET4 Clontech, but now marketed by Life Technologies
15. Electroporation Apparatus Bio-Rad Corp., Gene Pulser II SystemÒ
16. Miroprojectile Bombardment Apparatus Bio-Rad Corp.
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Figure 1. Flow chart of Tangible Property Transfers for pZPsC
Figure 2. Flow chart of Tangible Property Transfers for pBin19hpc
Source: Compiled by Maria Jose Amstalden Sampaio while on an IP Management training internship with
ISAAA. For references quoted, see list of references at the end of this document.
Source: Compiled by Maria Jose Amstalden Sampaio while on an IP Management training internship with
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These four categories are further expanded
into 43 sub-categories yielding over 70 US
and ex-US patents that appear to comprise the
intellectual property rights of this version of
GoldenRice. Fifteen instances of tangible
property rights connected to the development
of the product were also identified, (See
Section 4.2 above), and those rights are
summarized and included in Table 1.
Please refer to Table 3 at the end of this Section
for the entire Product Clearance Spreadsheet.
4.3.1 Plant/Seed Source
The transformed rice line, TP 309 (Taipei 309),
a japonica rice, was obtained by ETH-Zurich
from IRRI in the mid-1980s without any
known information or conditions that IRRI
may have attached at that time.
4.3.2 Gene Constructs (cloning
vectors)
Both pGEM4 (Promega) and pBluescriptKS
(Staratagene) were used in the production of
GoldenRice. The vector pGEM4 was critical
to the generation of pZLcyH and the vector
pBluescriptKS was critical to the generation
of pBin19Hpc.
4.3.2.1 The plant transformation vector,
pBin19Hpc
pBin19Hpc is a highly complex construct,
with a wide range of components that are
potentially covered by numerous patents and
MTAs:
• Plant gene promoters identified as
Camv35S as used in this construct is
covered by patents held by Monsanto
Company in the US and certain other
countries.
Figure 3. Flow chart of Tangible Property Transfers for pZLcyH
pZLcyH



























3 Note that here is a four-way patent litigation involving the Agrobacterium transformation system and precise ownership cannot
be established at this stage.
• The Gt1 promoter may be covered by
patents held by The University of
California and the National Foods
Research Institute (Japan).
• The nptII (kanamycin resistance) marker
may be covered under a patent held by
Japan Tobacco.
• The pea Rubisco Small subunit transit
peptide may be covered by patents held
by Plant Genetic Systems and Rhone-
Poulenc Agro.
• The aphIV marker (hygromycin resistance)
may be covered by patents held by Eli Lilly.
• The psy (phytoene synthase) gene may be
covered by patents held by Amoco,
DuPont, Zeneca, Kirin Brewery, and ICI.
• The crtI (phytoene desaturase) gene may
be covered by patents held by Amoco
Corp. and DuPont Corp.
4.3.2.2 The plant transformation vector,
pZPsc
pZPsc is another highly complex construct,
with a wide range of components that are
potentially covered by numerous patents and
MTAs:
• Plant gene promoters identified as
Camv35S as used in this construct is
covered by patents held by Monsanto
Company in the US and other
countries.
• The Gt1 promoter may be covered by
patents held by The University of
California and the
National Foods Research Institute (Japan).
• The pea Rubisco Small subunit transit
peptide may be covered by patents held
by Plant Genetic Systems and Rhone-
Poulenc Agro.
• The psy (phytoene synthase) gene may be
covered by patents held by Amoco,
DuPont, Zeneca, Kirin Brewery, and ICI.
• The crtI (phytoene desaturase) gene may
be covered by patents held by Amoco and
DuPont.
4.3.2.3 The plant transformation vector,
pZLcyH
pZLcyH is a highly complex construct, with a
wide range of components that are potentially
covered by numerous patents and MTAs:
• Plant gene promoters identified as
Camv35S as used in this construct is
covered by patents held by Monsanto
Company in the US and other
countries.
• The Gt1 promoter may be covered by
patents held by The University of
California and the
National Foods Research Institute (Japan).
• The pea Rubisco Small subunit transit
peptide, may be covered by patents held
by Plant Genetic Systems and Rhone-
Poulenc Agro. It was provided by Kirin
Brewery Co., Ltd.
• The aphIV marker (hygromycin resistance),
may be covered by patents held by Eli Lilly.
• The lcy (lycopene cyclase) gene, may be
covered by patents held by Kirin Brewery,
Amoco Corp., Yissum RDC, University of
Maryland, Centra National de al
Recherche




The intellectual property landscape in
transformation vectors, techniques, and
regeneration is also quite complex, with
numerous patents having potentially
overlapping claims.
• Agrobacterium transformation (general) is
connected to a considerable array of
potentially applicable patents, with
assignees such as Max Planck
Gesellschaft, Cetus Corp.,
Biotechnica Int., Inc., among others.3
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• Agrobacterium transformation (monocots)
is likely to be connected to a series of
patents, with assignees such as Max Planck
Gesellschaft, Japan Tobacco Inc., and the
NRC of Canada.
• Co-transformation technique may be
covered by several patents, both in general
terms, with the patent assignee being
Columbia University, and in more specific
terms (i.e, as in co-transformation of
monocots), with the patent
assignee being Japan Tobacco, Inc.
• Rice regeneration technology is patented,
with the NRC of Canada and Kirin Beer
Corp. of  Japan as assignees. These patents
may apply to the GoldenRice product.
4.3.4 DNA amplification
PCR was not used in the construction of the
expression cassettes at ETH-Zurich but the
possibility that PCR was used in the
construction of one of the components and/
or other up-stream vectors remains a
possibility. We did not investigate this further.
We decided, however, at least for
informational purposes, to include in the list
the fundamental PCR and Taq polymerase
patents, whose original assignees are Cetus
Corp. and Hoffman-La Roche. Note that
recent court determinations may change the
enforcement of these patents in certain areas
and may involve Promega Corp. in the final
decisions.
14 Table 3. Product Clearance Spreadsheet for GoldenRiceTM
1. Plant source Primary Patent Details
Source Patent no. Title Inventor(s) Assignee Filing Issue
date date
Common name rice
Scientific name Oryza sativa





Note that in the USA, the term of a utility patent depends on when the patent application was filed. If the patent issued from an application filed
prior to June 8, 1995, the term is the later of (1) 17 years from the date if issuance of the patent, or (2) 20 years from the first U.S. filing date for the
patent. If the patent issued from an application filed on or after June 8, 1995, then the term is 20 years from the first U.S. filing date for the patent.
For further information, see http://www.patents.com/patents.
continued...
15
Table 3 continued. Product Clearance Spreadsheet for GoldenRiceTM
2. Gene construct Primary Patent Details
(cloning vectors) Source Patent no. Title Inventor(s) Assignee Filing Issue
date date
Promega Corp.: US4766072 Vectors for in vitro Jendrisak Promega Corp. 17-Jul-85 23-Aug-88
pGEM4 was used production of RNA et al.
 in the construction copies of either strand
of pGt1lcyH of a cloned DNA
 (below) sequence.
Stratagene Corp.: US5128256 DNA cloning vectors Huse et al. Stratagene 20-Apr-89 7-Jul-92
pBluescriptKS was with in vivo excisable
used in the plasmids.
construction of
pBaal3 (below),




of psy and lcy
(below).
US5188957 Lambda packaging Short and Stratagene 26-Feb-91 23-Feb-93
extract lacking beta- Kretz
galactosidase activity
US5286636 DNA cloning vectors Huse et al. Stratagene 21-May-92 15-Feb-94
with in vivo excisable
plasmids.
EP0286200 DNA cloning vectors Sorge et al. Stratagene 12-Jan-88 12-Oct-88
with in vivo excisable
plasmids.
WO8805085 DNA cloning vectors Huse et al. Stratagene 12-Jan-88 14-Jul-88




Table 3 continued. Product Clearance Spreadsheet for GoldenRiceTM
3. pBin19hpc Primary Patent Details
Source Patent no. Title Inventor(s) Assignee Filing Issue
date date
CAMV 35S US4407956 Cloned cauliflower Howell The Regents of 13-Mar-81 4-Oct-83
Promotor mosaic virus DNA as the University
a plant vehicle of California
US5352605 Chimeric genes for Fraley et al. Monsanto Co. 28-Oct-93 4-Oct-94
transforming plant cells
using viral promoters
US5858742 Chimeric genes for
transforming plant cells
using viral promoters Fraley et al. Monsanto Co. 24-Jun-96 12-Jun-99
WO8402913 Chimeric genes suitable Fraley and Monsanto Co. 16-Jan-84 2-Aug-84
for expression in plant Rogers
cells
35S Terminator None found
Gt1 Promotor JP63091085 Rice glutelin gene and Fukazawa Natl Food 6-Oct-86 21-Apr-88
preparation thereof Res Inst
WO9916890 Production of proteins
in plant seeds Lemaux Univ. of CA 30-Sep-98 8-Apr-99
et al.
nos terminator None found
transit peptide US5717084 Chimaeric gene coding Herrera- Plant Genetic 6-Jun-95 10-Feb-98
for a transit peptide and Estrella Systems N.V.,
a heterologous peptide et al. Bayer A.G.
US5728925 Chimaeric gene coding Herrera- Plant Genetic 28-Apr-95 17-Mar-98
for a transit peptide and Estrella Systems N.V.,
a heterologous et al. Bayer A.G.
polypeptide
USRE36449 Chimaeric gene for Lebrun Rhone- 17-Feb-98 14-Dec-99




Table 3 continued. Product Clearance Spreadsheet for GoldenRiceTM
3. pBin19hpc Primary Patent Details
Source Patent no. Title Inventor(s) Assignee Filing Issue
date date
npt II EP0927765 Method for selecting Komari Japan Tobacco 23-Jul-98 7-Jul-99
transformed cells Inc.
aph IV US5668298 Selectable marker for
development of vectors
and transformation
systems in plants Waldron Eli Lilly and Co. 7-Jun-95 16-Sep-97
psy (phytoene The hetero- US5545816 Phytoene biosynthesis Ausich Amoco Corp. 19-Jul 93 13-Aug 96
synthase) logous probe in genetically et al.








US5705624 DNA sequences Fitzmaurice N/A 27 Dec 95 6 Jan98
encoding enzymes et al.
useful in phytoene
biosynthesis
US5750865 Process for modifying Bird et al. Zeneca 2 Sep 94 12 May98




EP0471056 Biosynthesis of Ausich Amoco 4 Mar 91 19 Feb 92





Table 3 continued. Product Clearance Spreadsheet for GoldenRiceTM
3. pBin19hpc Primary Patent Details
Source Patent no. Title Inventor(s) Assignee Filing Issue
date date
JP3058786 DNA strand useful Misawa Kirin Brewery 5 Mar 90 13 Mar 91
for synthesis of et al. Co. Ltd.
carotinoid
WO9109128 DNA, constructs, Bird et al. Imperial 10 Dec 90 27 Jun 91
cells and plants Chemical
derived therefrom Industries PLC





WO9955889 Carotenoid bio- Cahoon E. I. Du Pont 22 Apr 99 4 Nov 99
synthesis enzymes  et al. Nemours
and Co.
crtI (phytoene Misawa/ US5530189 Lycopene biosynthesis Ausich Amoco 22 Jul 93 25 Jun 96
desaturase) Kirin Brewery in genetically  et al. Corp.
engineered hosts
WO9113078 Biosynthesis of Ausich Amoco 4 Mar 91 5 Sep 91
carotenoids in et al. Corp.
genetically engineered
hosts
WO9955888 Carotenoid bio- Cahoon E. I. Du Pont 21 Apr 99 4 Nov 99




Table 3 continued. Product Clearance Spreadsheet for GoldenRiceTM
3. pBin19hpc Primary Patent Details
























pBluescriptKS US, World Stratagene
and EU (see above
patentsmay for relevant
be applicable, IP and TP
please see  connections)
above.
continued...
20 Table 3 continued. Product Clearance Spreadsheet for GoldenRiceTM
3. pBin19hpc Primary Patent Details
Source Patent no. Title Inventor(s) Assignee Filing Issue
date date
Pgt1PsyH Pgt1PsyH was The rice glutelin
derived from 1 promoter (Gt1)
the plasmid  was obtained from
pKS1 (T. Okita). T. W. Okita,








pYPIET4 pYPIET4 Plasmid pYPIET4:
(N. Misawa) source of crtl
was derived linked to the
from the binary transit peptide
plant express- sequence of the
ion vector pea Rubisco small
pBI121,pur- subunit (tp).
chased from Obtained from
Clontech N. Misawa of the
Laboratories, Kirin Brewery
now marketed Co., Ltd., Yokohama ,
by Life Japan. Misawa




Table 3 continued. Product Clearance Spreadsheet for GoldenRiceTM
4. pZPsc Primary Patent Details
Source Patent no. Title Inventor(s) Assignee Filing Issue
date date
components:
35S Promotor See above
35S Terminator See above
Gt1 Promotor See above
nos terminator See above
transit peptide See above
psy (phytoene See above
synthase)




pPZP100, Agrobacte- Paul Maliga



















22 Table 3 continued. Product Clearance Spreadsheet for GoldenRiceTM
5. pZLcyH Primary Patent Details
Source Patent no. Title Inventor(s) Assignee Filing Issue
date date
components:
35S Promotor See above
35S Terminator See above
Gt1 Promotor See above
aph IV See above
lcy (lycopene
cyclase) A hetero- US5429939 DNA sequences Misawa Kirin Beer 23 Oct 91 4 Jul 95
logous probe useful for the  et al. Kabushiki







US5530188 Beta-carotene Ausich Amoco 21 Jul 93 25 Jun 96
biosynthesis in et al. Corp.
genetically engineered
hosts
US5589581 DNA sequences Misawa Kirin Beer 10 Mar 94 31 Dec 96
useful for the et al. Kabushiki
synthesis of Kaisha
carotenoids
US5656472 Beta-carotene Ausich Amoco 7 Jun 95 12 Aug 97
biosynthesis in et al. Corp.
genetically engineered
hosts
US5792903 Lycopene cyclase gene Hirschberg Yissum RDC 7 Mar 95 11 Aug 98
et al. Jerusalem,
Univ. of MD
EP0393690 DNA sequences Misawa Kirin Beer 20 Apr 90 24 Oct 90
useful for the et al. Kabushiki
synthesis of carotenoids Kaisha
continued...
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Table 3 continued. Product Clearance Spreadsheet for GoldenRiceTM
5. pZLcyH Primary Patent Details
Source Patent no. Title Inventor(s) Assignee Filing Issue
date date
EP0699765 DNA, constructs,
cells and plants derived
therefrom Bird et al. Zeneca Ltd. 10 Dec 90 6 Mar 96
EP0820221 Lycopene cyclase gene Hirschberg Yissum 5 Mar 96 28 Jan 98
et al. RDC Jerusalem
WO9628014 Lycopene cyclase gene Hirschberg Yissum 5 Mar 96 19 Sep 96
et al. RDC Jerusalem
WO9636717 DNA sequences Kuntz Centre National 17 May 96 21 Nov 96
encoding a lycopene de la Recherche
cyclase, antisense Scientifique Kuntz
sequences derived
therefrom and their
use for the modification
of carotenoids levels
in plants





WO9955887 Carotenoid Cahoon E. I. Du Pont 16 Apr 99 4 Nov 99
biosynthesis et al. Nemours
enzymes and Co.
WO9963055 Genes of carotenoid Cunning- Univ. of MD 2 Jun 99 9 Dec 99
biosynthesis and ham and
metabolism and Sun
methods of use thereof
continued...
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Table 3 continued. Product Clearance Spreadsheet for GoldenRiceTM
5. pZLcyH Primary Patent Details
Source Patent no. Title Inventor(s) Assignee Filing Issue
date date
plasmid sources:
pPZP100, Agrobacterium Paul Maliga





pGT1LcyH Consturct Original source
contains: lcy, of components
aphIV in pGT1LcyH
expression still need to be
cassettes. determined.
The lcy gene is
likely from Beyer.








Table 3 continued. Product Clearance Spreadsheet for GoldenRiceTM
6. Transformation vectors, Primary Patent Details















their use Leemans Max Planck 31 Oct 86 4 May 88
et al. Gesellschaft
(DE)
EP0270822 Stable binary Leemans Max Planck 30 Oct 87 15 Jun 88
agrobacterium and Gesellschaft
vectors and Deblaere (DE)
their use
WO8504899 Methods and Gelfand Cetus Corp. 16 Apr 85 7 Nov 85
vectors for and Barton
transformation
of plant cells
WO8603516 Plant transformation Buchanan Biotechnica 13 Dec 85 19 Jun 86
vector and Int. Inc.
Cannon
continued...
26 Table 3 continued. Product Clearance Spreadsheet for GoldenRiceTM
6. Transformation vectors, Primary Patent Details
techniques, plant Source Patent no. Title Inventor(s) Assignee Filing Issue
regeneration date date
Agrobacterium US5591616 Method for trans- Hiei Japan 3 May 94 7 Jan 97
mediated forming mono- and Tobacco Inc.
transformation/ cotyledons Komari
vectors EP0257472 Transgenic mono- De La Pena Max Planck 13 Aug 87 2 Mar 88
(monocotyledons) cotyledonous plants, et al. Gesellschaft




EP0604662 Method for trans- Hiei Japan 6 Jul 93 6 Jul 94
forming mono- and  Tobacco Inc.
cotyledon Komari
EP0672752 Method of trans- Saito Japan 1 Sep 94 20 Sep 95




WO8603776 Process for preparing Hernal- Plant Genetic 20 Dec 85 3 Jul 86
genetically stably steens Systems N.V.
transformed mono- et al.
cotyledonous plant
cells
WO9209696 Process for trans- DHalluin Plant Genetic 21 Nov 91 11 Jun 92
forming mono- and Gobel Systems N.V.
cotyledonous plants
WO9419930 Enhanced regeneration Nehra NRC of Canada 10 Mar 94 15 Sep 94
system for cereals et al.
WO9967357 Agrobacterium- Dong et al. Rhone- 22 Jun 99 29 Dec 99




Table 3 continued. Product Clearance Spreadsheet for GoldenRiceTM
6. Transformation vectors, Primary Patent Details
techniques, plant Source Patent no. Title Inventor(s) Assignee Filing Issue
regeneration date date
Co-transformation US4399216 Process for inserting Axel et al. The Trustees of 25 Feb 80 16 Aug 83
technique: DNA into eucaryotic Columbia Univ.
Two non-linked cells and for producing in the City
plasmids transformed proteinaceous materials. of New York
simultaneously. US4634665 Process for inserting Axel et al. The Trustees of 11 Aug 83 6 Jan 87
DNA into eucaryotic Columbia Univ.
cells and for producing in the City
proteinaceous materials. of New York
WO8303259 Method for introducing Axel et al. The Trustees of 8 Mar 83 29 Sep 83
cloned, amplifiable Columbia Univ.
genes into eucaryotic in the City
cells and for producing of New York
proteinaceous products
US5731179 Method for introducing Komari Japan 8 Aug 95 24 Mar 98
two T-DNAs into plants et al. Tobacco Inc.
and vectors therefor
EP0687730 Method of transforming Komari Japan
plant and vector et al. Tobacco Inc. 12 Jun 94 20 Dec 95
therefor
WO9516031 Method of transforming Komari Japan 6 Dec 94 15 Jun 95
plant and vector et al. Tobacco Inc.
therefor
Agrobacterium US5186800 Electroporation of Dower Bio-Rad . 14 Mar 90 16 Feb 93
electroporation prokaryotic cells Laboratories,
Inc
EP0765397 Method for introduction Leer et al. Nederlandse 16 Jun 95 2 Apr 97
of genetic material into Organisatie




28 Table 3 continued. Product Clearance Spreadsheet for GoldenRiceTM
6. Transformation vectors, Primary Patent Details
techniques, plant Source Patent no. Title Inventor(s) Assignee Filing Issue
regeneration date date
Agrobacterium WO9535389 Method for introduction Leer et al. Nederlandse 16 Jun 95 28 Dec 95
electroporation of genetic material into Organisatie
microorganisms and  Voor Toegepast
transformants obtained
therewith
Transformation US4237224 Process for producing Cohen Stanford 4 Jan 79 2 Dec 80
(general) biologically functional and Boyer University
molecular chimeras
Regeneration US5350688 Method for Matsuno Kirin Beer 16 Jun 92 27 Sep 94
of rice regeneration of rice and Kaburshiki
plants Ishizaki Kaisha
WO9419930 Enhanced regeneration Nehra NRC Canada 10-Mar-94 15-Sep-94
system for cereals et al.
continued...
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Table 3 continued. Product Clearance Spreadsheet for GoldenRiceTM
7. DNA Amplification Primary Patent Details
techniques, plant Source Patent no. Title Inventor(s) Assignee Filing Issue
regeneration date date
PCR Technique US4683202 Process for amplifying Mullis Cetus 25 Oct 85 28 Jul 87
nucleic acid sequences thereafter to
Hoffman-
La Roche
US4683195 Process for amplifying, Mullis Cetus 7 Feb 86 28 Jul 87
detecting, and /or- et al.
cloning nucleic acid
sequences





EP0509612 Process for amplifying Mullis Hoffman- 27 Mar 86 21 Oct 92
and detecting nucleic et al. La Roche
acid sequences
EP0502588 Process for amplifying
nucleic acid sequences Mullis Hoffman- 27-Mar-86 9-Sep-92
La Roche
EP0502589 Kit for use in amplifying Mullis Hoffman- 27-Mar-86 9-Sep-92
and detecting nucleic et al. La Roche
acid sequences
Taq polymerase US4889818 Purified thermostable Gelfand Cetus
enzyme et al. thereafter 17 Jun 87 26 Dec 89
to Hoffman-
La Roche
EP0258017 Purified thermostable Erlich Cetus 21 Aug 87 2 Mar 88






4.4 Discussion of Special Cases
Throughout the course of the GoldenRiceTM
product deconstruction, questions arose that
sometimes could not be readily answered. We
discuss these and address their implications
in the sub-sections below.
4.4.1 The nptII gene
An examination of the pBin19Hpc expression
cassette reveals that the selectable marker nptII
lies between the LB and RB (left and right
border regions) of the binary vector. However,
during the course of the deconstruction, we
could not rationalize this orientation. The
source of nptII is pBin19 (see Bevan, 1984),
and in this construct it is clearly outside of the
LB-RB region. Through communication with
Peter Beyer, we ascertained that nptII had
likely moved to this new location.
Although intriguing as a scientific question,
for our purposes its real importance was within
the context of the IP that might be associated
with nptII, contingent on its specific location
in the transformation vector. Whereas the nptII
gene should fall outside of the T-DNA region,
on the distal side of the plasmid, in pBin19Hpc
it is within the T-DNA region. Patent
EP0927765, entitled Method for Selecting
Transformed Cells, states in Claims #8&9 that
A method for producing a rice transformant
by a desired gene comprising: a) providing a
strain belonging to the genus Agrobacterium
which has a plasmid containing a
paromomycin (nptII) resistance gene and a
desired gene, in the T-DNA region in said
plasmid, in such a way as to allow expression
of each of said genes. It appears that the
location of nptII will have significant impact
on the likelihood of the product being
covered under this patents claims. Indeed,
what first appears as an anomaly or scientific
curiosity can (very rapidly) complicate the IP
landscape of the product.
4.4.2 Method of Plant Transformation
The method by which the precultured,
immature rice embryos were transformed using
Agrobacterium is first referenced in Uze et al.,
1997. The Uze reference lists two techniques
of transformation: with a wounding
pretreatment (biolistic bombardment) or
without, followed by immersion in
Agrobacterium. If the wounding pretreatment
had been used, patent WO9209696 may
apply, since in the claims it describes A
method of transforming, with a DNA, a
genome, particularly the nuclear genome of
a monocotyledonous plant.....comprising the
steps of, wounding and/or degrading either an
intact tissue of said plant that is capable of
forming compact embryogenic sector thereof,
obtained from said intact tissue of said plant,
so as to render a cell of said intact tissue of
callus competent with respect to uptake of
said DNA, integrative transformation of said
DNA in said plant genome and regeneration.
Additionally, if the biolistic pretreatment had
been used, then the array of patents associated
with microprojectile bombardment of plants
and/or plant tissues would have required
careful scrutiny, along with all potentially
applicable licenses. However, Professor
Potrykus informed us that the procedure used
was osmoticum treatment of 7-10 day old calli
(without bombardment).
4.4.3 Overlapping Patent Claims in
Carotenoid Biosynthetic Option
Genes
The interpretation of claims in patents dealing
with the genes and enzymes in the carotenoid
biosynthetic option(s) can be extraordinarily
complex, with certain patents having claims
that appear to cover multiple enzymes/genes
in the option. The homologous carotenoid
biosynthesis gene clusters found in Erwinia
uredovora (Kirin) and Erwinia herbicola
(Amoco) are examples. There appear to be
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overlapping patent claims with several of the
patents we have listed in Table 1. For example,
• US5589581 has claims apparently
covering the genes encoding zeaxanthin
glycosylase, lycopene cyclase, phytoene
dehydrogenase, and phytoene synthase.
• WO9113078 has claims apparently
covering genes encoding geranylgeranyl
pyrophosphate synthase, phytoene
synthase, lycopene cyclase, and others.
• US5429939 has claims apparently
covering genes encoding enzymes for
phytoene synthase, phytoene
dehydrogenase, lycopene cyclase, and
others.
From a practical standpoint, the patents listed
on Table 1 dealing with the three carotenoid
biosynthetic genes in GoldenRice should
not necessarily be considered as mutually
exclusive in terms of their claims. The
possibility of substantial overlap is quite likely.
4.4.4 Interpreting Patent Claims: From
Greater to Lesser Uncertainty
Reviewing potentially applicable patents, and
determining whether their claims might apply
to the GoldenRice product is not a simple
yes or no situation. Rather, it is a process of
decreasing levels of uncertainty, and
appropriate judgment is necessary. As an
example, we can consider four patents dealing
with genes in the carotenoid biosynthetic
option.
• US5744341(not listed in Table 1) is highly
unlikely to be attached to the
GoldenRice product. Its claims
specifically relate to genes for the enzymes
epsilon cyclase, isopentenyl
pyrophosphate isomerase, and beta-
carotene hydroxylase; these genes have
not been used in the production of
GoldenRice.
• US5656472 is somewhat likely to be
attached to the GoldenRice product and
requires more careful evaluation. This
patent describes a gene for lycopene
cyclase, which is associated with
GoldenRice. The claims call for 80%
identity with said gene, as well as
hybridization under high stringency
conditions (Southern blot). To determine
what the relationship is between the gene
in question and the patent claim would
involve some laboratory experiments.
• WO9955888 is more likely to be attached
to the GoldenRice product. This patent
deals with a carotene desaturase. The
claims are broadly written, (e.g., claim #2,
an isolated nucleic acid fragment that is
substantially similar to an isolated nucleic
acid fragment encoding all or a substantial
portion of (a zeta carotene desaturase).
• WO9907867 is highly likely to be
connected to the GoldenRice product
and deserves special attention. The claims
are broadly and skillfully written, such that
any transformation process of a plant seed
with a gene from the carotenoid
biosynthetic option leading to an alteration
of xanthophyll levels is likely to be
covered. In the case of GoldenRice,
accumulation of zeaxanthin (a
xanthophyll) was detected in the
pBin19hpc transformants.
4.4.5 Pea Rubisco Small Subunit
Transit Peptide
The transit peptide was obtained from a
company, with a letter specifying restrictions
on use attached. However, this situation is
further complicated, since that company had
originally obtained the transit peptide from Jeff
Schell, who is a co-inventor on the patents
US5717084 and US5728925; the assignee is
Plant Genetic Systems N.V. These patents
appear to substantially cover the use of the
transit peptide. The question that needs to be
sorted out, particularly in terms of tangible
property under what conditions that company
acquired the gene from Plant Genetic Systems
(now AVENTIS).
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5. IP Management Implications
5.1 Introduction
The development of GoldenRice, a
transgenic japonica rice with elevated levels
of pro-Vitamin A producing beta carotene, has
gained a great deal of worldwide media
attention. It has been proposed as a way to
reduce blindness and its related suffering
which results from Vitamin A deficiency.
Further, as a transgenic food, GoldenRice
is seen as the agri-biotech industrys poster
child andby donating the IP and TP
componentsa tangible way for the industry
to show their concern for humankind. Wide
availability of GoldenRice would, it is
argued, focus attention on the societal good
of plant biotechnology. It is a tangible example
of the benefits which biotechnology has
already brought to humanity through the
pharmaceutical industry in which virtually all
new drug releases are produced using
essentially the same kinds of biotech processes
and components that were used to produce
GoldenRice. Biotech food has been plagued
by detractors, particularly in Europe, whose
scientifically unsound arguments belie a
hidden agenda that is more anti-corporate than
pro-environment, as is so loudly proclaimed.
In spite of these distractions from Europe and
elsewhere, there is broad agreement among
the leadership of most developing and
transitional countries, that appropriate IP rights
protection is necessary to entice investment
in their economy, provide additional
employment for their citizens, and produce
hard currency through the export of high tech
products. These leaders recognize that the
enforcement of IP related laws protect not only
the innovations and discoveries of foreign
investors, but also protect the increasingly
occurring discoveries of their own scientists,
engineers, and entrepreneurs. In this way the
countries get closer towards obtaining the food
security and technological standard of living
that is common in the industrialized world.
Although skeptics reject such development
efforts as being neo-colonial, few will deny
that food biotechnology products have a
tremendous potential to decrease hunger and
suffering, increase food security, and reduce
many of the negative environmental impacts
of modern agricultural practices.
Given all of these benefits that GoldenRice
can potentially produce, questioning the
legitimacy of the IP and TP rights issues related
to its discovery and dissemination may be
considered a questionable activity. Yet such
questions must be asked. The questions
behind this study involve what IP and TP rights
limitations, if any, stand in the way of the broad
distribution of GoldenRice to the worlds
resource-poor who can benefit most. Further,
once such questions are identified, articulated,
and catalogued it must be asked how such
obstacles can be overcome.
5.2 Potentially Applicable Patents
 (or IP) to the Current Form of
GoldenRiceTM
Patents grant only negative rights. That is, a
patent holder can prevent others, for a
specified period of time (typically 12  20
years, depending upon a countrys patent
laws), from making, using, exporting or selling
items infringing the issued claims of his/her
patent. Of course the patent holder, through
license or assignment, can grant permission
to others to function under their issued patent
claims.
TP rights are established under a countrys laws
governing personal property and contracts.
These rights too, are enforced on a country-
by-country basis. However, unlike IP rights,
personal property (and most aspects of
contract law) rights are much more uniformly
acknowledged and enforced around the
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world, even in countries which do not have
enforceable IP laws. Further, such rights
seldom have a time limitations on their
enjoyment or enforcement.
Trademarks are claimed on a country-by-
country basis. Like other personal property
rights trademarks seldom have a time
limitation on their enforcement.
Domain names, a new sort of right that has
developed with the advent of the World Wide
Web (WWW), require re-registration from
time-to-time. Such re-registration, with a minor
fee, maintains worldwide exclusivity of a
particular domain name. Adjudication of
alleged domain name violations are similar to
that of other personal property rights.
The present study identified between zero and
40 plus patents applying to the product
depending on the country where the current
form of GoldenRice would be used (for a
total of approx. 70 patents applying across
different countries). It must be clearly stated
that, because patents are country
specific, not all 70 patents apply to all
of the major rice producing, exporting,
importing and consuming countries.
Further, many of the developing and
transitional countries for which
GoldenRice will have the greatest
positive impact, have the fewest patents.
Widespread distribution of the product would
require licenses from zero to a dozen or so
entities for the IP components, plus
agreements from another dozen entities for the
TP transfer and use. In addition to the patented
materials, processes, and reagents that the
inventors used, certain trademark related issues
may need to be addressed as GoldenRice
is widely distributed. All in all, the widespread
release of the current version of GoldenRice
would require significant licensing activity if
it is to legitimately become available to the
world, either commercially or for humanitarian
purposes.
Until recently, individuals and firms from the
industrialized world typically withheld
patenting in developing countries. The
developing countries thereby were denied
access to the latest technological
advancements, except in some cases as
markets for such new products. In more recent
years however, to induce the introduction of
technologically advanced manufacturing into
developing countries with their abundant
supply of qualified yet inexpensive labor,
many developing countries have signed the
WTO/TRIPS agreements. These international
agreements require the signatories to establish
and maintain a prescribed level of IP rights
protection. Thus, with the rise of a more global
economy, technologically advanced products
such as GoldenRice may be produced,
distributed and consumed on a worldwide
basis. Therefore, the effects of IP and TP rights
matters must be considered on a more global
scale than was previously necessary.
Table 4 lists the number of patents that might
be applying on a country per country basis
for the 15 top rice producing, exporting and
importing countries. For example in China,
the worlds leading rice producer, there are
only 11 patents that apply to the current form
of GoldenRice analyzed in this report. In
Thailand and in Iran, the worlds leading rice
exporter and rice importer, respectively, no
patents have been identified as currently
impinging upon GoldenRice. India, second
in world rice production, has 5 patents
covering the studied versions of GoldenRice
while rice producers in Vietnam, the worlds
second biggest exporter of rice, would require
licenses to nine patents in order to obtain
freedom-to-operate. Grain importers to Brazil,
the worlds second biggest importer of rice,
would require licenses to 10 patents in order
to obtain full freedom under known IP rights
to import GoldenRice into this South
American country.
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Table 4: Major Rice Producing, Exporting and Importing Countries (FAO 1997) and the Number of
Applicable Patents to GoldenRiceTM in its Current Form
Production
Country Million MT % of World No. of Patents
China 198.47 34.6 11
India 123.01 21.5 5
Indonesia 50.63 8.8 6
Bangladesh 28.18 4.9 0
Vietnam 26.40 4.6 9
Thailand 21.28 3.7 0
Myanmar 18.90 3.3 0
Japan 12.53 2.2 21
Philippines 11.27 2.0 1
Brazil 9.33 1.6 10
USA 8.12 1.4 44
South Korea 7.10 1.2 10
Pakistan 6.55 1.1 0
Egypt 5.59 1.0 0
Nepal 3.71 0.6 0
Total World 573.30 100.0
Export
Thailand 3.24 17.9 0
Vietnam 3.00 16.6 9
USA 2.30 12.7 44
India 2.13 11.8 5
Pakistan 1.77 9.8 0
China 1.01 5.6 11
Uruguay 0.65 3.6 0
Australia 0.65 3.6 15
Italy 0.63 3.5 29
Argentina 0.54 3.0 0
Guyana 0.29 1.6 0
Spain 0.27 1.5 27
Egypt 0.20 1.1 0
UAE 0.18 1.0 4
Benelux 0.14 0.8 34
Total World 18.10 100.0
Import
Iran 0.97 5.2 0
Brazil 0.82 4.4 10
Nigeria 0.73 3.9 0
Philippines 0.72 3.9 1
Iraq 0.68 3.7 0
Saudi Arabia 0.67 3.6 0
Malaysia 0.64 3.4 0
South Africa 0.59 3.2 5
Japan 0.57 3.1 21
Cote DIvoire 0.47 2.5 10
Senegal 0.40 2.2 10
UK 0.39 2.1 35
France 0.37 2.0 37
Indonesia 0.35 1.9 6
United States 0.36 1.9 44
Total World 18.60 100.0
Note: Appendix A provides a list of the designated patent numbers that may apply in each of the countries listed in this table.
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The above always supposes that the TP issues
have been resolved with the Table 4 only
addressing IP rights, which can vary widely
from country to country. TP rights that are
related to this version of GoldenRice may
be more uniformly applied across all
countries, whether the country is considered
to be developing, transitional or industrialized.
5.3 Product vs. Process vs. Use
Claims4
Depending on the country in which one files,
patent claims may be granted for different
kinds and levels of inventions. The categories
of granted claims most applicable to this study
are:
• Products per se  (covering any yet-to-be





These categories of claims are not specifically
identified as such, only a thorough reading
will indicate the distinctions between them.
Claims may be worded to cover product per
se, products-by- process or uses. However, the
fourth category of claims listed above is of
particular importance here because whereas
product per se, product-by-process and
use claims generally extend to the products
that embed the new discoveries, process
claims or claims for the claimed technical
procedures do not extend to the products that
are produced by the claimed processes. What
is of great important for process claims is the
location where (i.e. in which country) the
process is applied.
For clarity, the three examples below illustrate
claims on Product, Process, and Product/
Process patents, in terms of their claim
structures:
• Product: US5589581, DNA sequences
useful for the synthesis of carotenoids,
claims stipulate isolated and purified DNAs
which encode enzymes involved in the
biosynthesis of several carotenoids.
• Process: EP0604662, Method of
transforming monocotyledon, claims




Enhanced regeneration system, claims
stipulate both the methods for the
regeneration of cereal plants, as well as the
transgenic cereal plants (including rice)
produced in the process.
In the case of GoldenRice, much of the work
was done in Switzerland. As a consequence,
for  any  process claims a license for such
claimed processes is required if the claims to
the processes are issued in Switzerland.
However, if the product had been made in a
country where those process claims have
not issued, then a license for such claimed
processes would not be required. This is the
crux of this matter. If a product is produced in
a country using process X and process X is
not patented in that country, then the export
of the product so produced using process X
to another country where process X is
patented does not require a license for process
X. The reason is that the product was
produced in a country where process X was
not patented and because process patents do
not extend to the products that are produced
by the process. The country where the process
is applied is the determining factor.
In contrast, product per se claims extend to
any form of the claimed product. A scenario
that illustrates this would be this.
Suppose that a researcher in country M
transforms a plant with  gene G, in a country
4 See also Lesser (1991) for an concise discussion on issues and approaches on patent protection in the developing world.
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where the gene G is not patented. Once the
transformed product is exported to another
country, say country N, where a patent
claiming gene G has issued, a license for the
transformed plant and any product using or
containing the transformed plant that contains
gene G in country N would likely be required,
irrespective of where the transformation work
had been done.
Some of the patent claims applicable to
GoldenRice cover processes. The primary
ones are listed in Table 5. Of the total patents
identified, 26 seem to contain process claims.
Other of the patents (not listed in Table 5) has
claim structures which are a mix of process
claims and product per se claims. In
Switzerland, where much of the original
GoldenRice research was done, only the first
12 patents listed in Table 5 have issued. As a
consequence, someone developing a
GoldenRice product in Switzerland would
require licenses under these 12 patents but
not under the remainder of the patents listed
in Table 5.
Similarly, a researcher who obtained
GoldenRice that had been transformed in
Switzerland for use in a country where none
of the process claims of the 12 patents were
issued would not require a license under any
of the 12 patents.
Whereas sorting out the types of patents and
types of licenses that may be required appears
a complex task, process patents at least
simplify the IP landscape in many situations
and countries.5
5.4 The Important Distinction between
IP and TP
Although we have discussed at several loca-
tions in this document the distinction between
IP and TP rights, it is worth reviewing briefly
the practical implications. Scientists have tra-
ditionally exchanged materials among them-
selves for research purposes and this system
has served the scientific community very well.
Such exchanges are often formalized through
material transfer agreements (MTA) that stipu-
late the conditions by which materials are pro-
vided to a third party (including matters on
confidentiality, under what conditions, if any,
the material may be transferred to another
party, what happens if an invention takes
place based on work with the material, etc.).
What is often ignored is that such transferred
material (which is the subject of Technical
Property or TP) may contain intellectual prop-
erty (IP) of others and that MTAs typically do
not provide the recipient with rights to use
such IP. Similarly, even if the right for using IP




























5 It should be noted, however, that a bill which has been in the US Senate for several years calls for a change in this system.
Should the bill pass, any product imported into the USA and produced abroad by a process patent granted in the USA would
require a license.
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embedded in the transferred material has been
granted through licenses, such licenses do not
a priori provide authorization to use the ma-
terial (or TP) which was originally transferred.
Suppose researcher X constructs a vector with
the following components:
a. a synthetic gene constructed in his/her
laboratory (and files a patent application)
b. the 35S promoter (owned by Monsanto
and obtained through an MTA from
Monsanto for research purposes only)
c. a plasmid which is in the public domain.
Researcher X now transfers that construct to
another researcher, Y, with an MTA for
research purposes only. If researcher Y then
wishes to use a product containing the
construct, the following agreements may be
necessary:
• A license from researcher X for use of the
synthetic gene (TP) and any related patents
that may have been granted (IP) as specified
in a above.
• A license from Monsanto for use of the 35S
promoter
• A license from researcher X for use of the
plasmid (TP). Note that despite the fact that
the plasmid is in the public domain,
researcher Y obtained it under an MTA
and therefore requires a license to use that
TP.
As a consequence, resolving the IP and TP
issues becomes often much more complex
than originally envisaged, particularly if MTAs
are involved. These MTAs are often prepared
without consideration for what happens when
research leads to a developed product. MTAs
are straightforward and provide an easy way
to access TP and advance research. Yet that
easy route often complicates life further down
the road. It should not be concluded that MTAs
are therefore to be avoided, quite on the
contrary, but the practical implications of
MTAs are often misunderstood.
5.5 IP Management Options or
Strategies
Many, perhaps most, people agree with the
humanitarian objective of making
GoldenRice available to resource-poor
farmers and rice consumers within developing
countries. The present preliminary FTO
analysis was conducted to better understand
the current situation so that options and
alternative future strategies might be discussed
and developed. Yet the alternative options
may be obscured by the desire to achieve the
valued end. This end is always very straight
forward, whether it is a private entity or a
public/non-profit entity that pursues it, namely
providing farmers with a superior product. The
typical difference between a public and a
private entity is that the private entity needs to
share in the benefits, but both must provide
superior products in order to survive. Evidently,
the way products are disseminated by the two
entities will vary also. Hence the IP
management options and strategies of most
private entities will be different to those of
public entities.
Table 6 lists the broad ranges of strategic
options that are available to any type of entity,
public or private. The options tackle the FTO
issue from different perspectives and are
discussed in the sub-sections below. Note that
our discussion of possible alternative strategies
will not address all the issues that may arise
from the commercialization of GoldenRice;
we are focusing our discussion specifically to
options on how to possibly overcome
obstacles related to making GoldenRice
available to resource-poor farmers.
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Table 6. Alternative and/or Complementary IP/TP Management Options to Obtaining Freedom-to-Operate
for GoldenRice
Title Emphasis Description Pros Cons
1. Invent Science and Research alternative ways • Less reliance on • Time consuming
around research based to develop pro-Vitamin A   patents owned • Costly research
current approach rice, generating new   by others • May not be feasible
patents inventions
2. Re-design Product Re-design each • Normally re-design • May require a few
constructs development construct to reduce number   is necessary after   additional years for
based approach of applicable patents,   successful research   product to be deve-
whenever possible synthesize   demonstration   loped (which in any
own genes to reduce reliance • Effective way to   case may be unavoid-
on TP of others   reduce IP issues   able from a scientific
  point of view)
3. IP/TP Humanitarian All FTO issues for all • Some companies A royalty-free license
Owners to approach GoldenRice related   (e.g. Zeneca and may still need to be
Relinquish focused on activities, commercial or   Monsanto) already negotiated, not least
Claims public perception otherwise, are eliminated   publicly declared for liability/indemnity
through public (or private)   that they will make reasons
statements and related   their technologies
activities by the certified   available for
owners/assignees of each set   GoldenRice
of IP/TP rights for making, • Greatly simplifies
having made, using, having   licensing negotiations
used, importing, exporting,
selling, and having sold all
GoldenRice plants, plant parts,
and all related products
and processes.
4. Ignore Short term All FTO issues for all • Lowest cost in the • Once product deployed
all IP and TP perspective GoldenRice related   short term   lawsuits may ensue
activities, commercial or • Potential future delay
otherwise, are ignored, and   of product distribution
research and product • Difficult relations with
development as well as plans   IP owners
for general distribution proceed.
continued...
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Table 6 continued. Alternative and/or Complementary IP/TP Management Options to Obtaining Freedom-
to-Operate for GoldenRice
Title Emphasis Description Pros Cons
5. Seek Licensing All FTO issues are resolved • Safest route • Complex
Licenses for approach by the process of any   leading to • Time consuming
all IP and TP party (individually or through   the distribution
consortia) acquiring an   of GoldenRice
appropriate (commercial • Ensures good
or other) license from   relations with IP
 the certified owners/   holders for future
assignees for each set   development of products
of IP/TP rights for the
GoldenRice related
activities that are of interest to
the licensee. This license may
be commercial in nature
(a grant to make, have made,
use, have used, import, export,
sell, or have sold all
GoldenRice plants and plant
parts and all related products
and processes) or a more
restrictive one as the licensee
and licensor mutually determine
to be required.
6. Mix of all Pragmatic, While research and • Effective route • Relatively complex
Options realistic development plans are   leading to • Relatively time
(1 to 5) made to optimize the   the distribution of    consuming
product, re-design of   GoldenRice
constructs and acquisition • Taking advantage of all
on TP is planned to   available options
minimize IP and TP conflicts • Ensures good relations
(OPTION 2); selected FTO   with IP holders for
issues are removed through   future development
public (or private) rescinding   of products
of rights by  selected holders
of certain IP/TP rights
(OPTION 3);  this moral
high ground is used to
leverage additional rights
holders to either rescind their
claims (OPTION 3) or to
reduce their demands within
the context of license
negotiations (OPTION 5).
In the end all remaining
unrescinded IP/TP rights can
be either licensed (OPTION 5)
or ignored (OPTION 4).
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5.5.1 OPTION 1: Invent Around
Current Patents
Research on alternative ways to develop pro-
Vitamin A rice, generating new inventions.
In certain cases it is possible to invent around
existing patents or inventions. Companies, for
example, will typically evaluate at the outset
whether it is advantageous to invest in research
to circumvent other corporations patents or
to license technologies from such competitors.
In the case of public entities, the equation of
the benefits and risks is very different. Quite
often, they do not have the same critical mass
in research nor do they necessarily have the
freedom to allocate resources to invent
around existing claims. In addition, in the case
of GoldenRice, it would significantly delay
the benefits to poor farmers even if inventing
around were possible. Hence this is not a
realistic option in this case for public entities
and NARS.
5.5.2 OPTION 2: Re-design Constructs
Re-design each construct to reduce number
of applicable patents, whenever possible
synthesize own genes to reduce reliance on
TP of others
The GoldenRice as announced by Potrykus/
Beyer in recent months is primarily the product
of basic research. Quite naturally, such
research products are rarely ready for
commercialization or widespread distribution
although the proof of concept has been
demonstrated in a few selected plants. In
practical terms, genes may have to be
optimized or new constructs made with
different promoters or selectable markers. It
can reasonably be expected that the same
would be true for the current version of
GoldenRice. As a consequence, this study
should provide the scientists and research
managers with some of the information needed
to design the constructs in such a way as to
reduce  the number of applicable patents (or
IP).
Re-design of constructs would also go a long
way towards reducing or even eliminating the
TP complexities since many genes can be
synthesized commercially at low costs and
public plasmids can be used without major
contractual limitations.
Re-designing the production of GoldenRice
for scientific reasons may be the most feasible
option available to deliver a high quality
product to resource poor farmers. Further, it
may also be the best complementary option
to reduce the IP and particularly the TP
complexity (see also Section 6.1.2 below for
further discussion) of such a re-designed
product.
5.5.3 OPTION 3: IP/TP Owners to
Relinquish Claims
All FTO issues for all GoldenRice related
activities, commercial or otherwise, are
eliminated through public (or private)
statements and related activities by the certified
owners/assignees of each set of IP/TP rights
for making, having made, using, having used,
importing, exporting, selling, and having sold
all GoldenRice plants, plant parts, and all
related products and processes.
With this option, the IP/TP rights holders
rescind all of their rights for all components of
GoldenRice. Then any entity involved with
GoldenRice would essentially be freed from
all IP and TP related obligations. It may not
necessarily mean that entities wishing to
distribute and use GoldenRice would not
have to enter into a royalty-free licensing
agreement with the owners of IP and TP since
such owners typically would want to ensure
that they do not bear any liabilities with a
product developed by third parties and for
which they, the technology donor, do not
receive any royalties.
41
This matter is dealt with through indemnity
clauses by which the recipient agrees to hold
the donor harmless of any liabilities that might
flow from making, using or selling the products
developed by the recipient. Commercial
licenses, whether royalty-free or not, generally
include indemnity clauses. No entity
knowingly wishes to allow another entity to
develop a product and then be held liable for
the product for which the entity had no control
over. This is especially true in cases where a
technology is given free of charge.
There may, however, be a significant time and
resource expenditure required to determine
which IP and TP rights are to be rescinded, to
authoritatively determine who the IP/TP rights
owners/assignees are, under what conditions,
if any, the IP/TP rights owners/assignees will
rescind their respective rights, and to conduct
the negotiations that may be necessary for all
rescission to take place. Moreover, there would
be a need to compile and manage information
relating to obtaining FTO in this manner.
Because IP/TP rights are accrued on a
country-by-country basis, such information
management is no small matter and would
have to be addressed on an on-going basis.
This option is appealing, but entities still face
the challenge of significant FTO management
requirements and solving liability/indemnity
issues.
5.5.4 OPTION 4: Ignore all IP and TP
All FTO issues for all GoldenRice related
activities, commercial or otherwise, are
ignored, and research and product
development as well as plans for general
distribution proceed.
On this option, the entities involved in the
development and distribution of
GoldenRice would ignore the claims of all
owners/assignees of each set of IP/TP rights
for all GoldenRice related activities.
This option may accrue risks from both patent-
related (IP) and private property-rights (TP)
owners/assignees who would feel slighted.
Such risks may vary widely according to the
degree of enforcement that the IP/TP rights
owners/assignees find within each country
where they claim IP/TP rights and to the
willingness of such owner/assignees to invoke
action against potential infringers.
This option has a significant appeal to a
number of entities, not least because of its
perceived ability to partially equalize the
resources and power differences between the
developing and industrialized portions of the
world. However, this option is likely to create
a negative attitude among the holders of
various IP/TP rights when advocates for the
resource-poor seek to obtain additional
biotechnology components in the future.
This option eliminates all need to ascertain
who are the IP/TP rights owners/assignees but
it flies in the face of current international
treaties signed by the majority of developing
countries and widely accepted national laws
in virtually every country of the world.
Another potentially more significant downside
with this approach is its potential impact on
future negotiations with those ignored IP/TP
rights owners/assignees. Future collaboration
and donations would most likely become
impossible under such a climate. It should be
noted here that in addition to obtaining
freedom to use a certain technology owned
by the entity owing a patent, licensing
agreements generally also allow for the transfer
of know-how and trade secrets which may be
very valuable in order to ensure high quality
products and faster or more efficient and less
costly product development.
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5.5.5 OPTION 5: Seek Licenses for all
IP and TP
All FTO issues are resolved by the process of
some party (individually or through consortia)
acquiring an appropriate (commercial or
other) license from the certified owners/
assignees for each set of IP/TP rights for the
GoldenRice related activities that are of
interest to the licensee. This license may be
commercial in nature (a grant to make, have
made, use, have used, import, export, sell, or
have sold all GoldenRice plants and plant
parts and all related products and processes)
or a more restrictive one as the licensee and
licensor mutually determine to be required.
This option appears at first glance to be a little
desired option. Indeed, in the short term it may
be so. It requires an overall IP/TP rights
management strategy that parallels the
scientific research and product development
effort for GoldenRice. It requires that some
entity definitively determine all IP/TP rights
owners/assignees, draft and negotiate
appropriate license agreements, report and
track the appropriate changes in the IP/TP
rights landscape over time, and confirm to the
various licensees all of these variables.
As a practical matter of license negotiation,
adopting this strategy may segment the various
licensees into different categories. Such
segmentation would likely be according to the
level of the licensees needs, with more
generous license terms being offered to the
poorest. Such segmentation might also result
from the licensors business plans, the
licensees level of capacity in IP/TP
management, issues of domestic production/
consumption vs. desire to export, regulatory
issues of biosafety/food safety, bans on the
transfer of certain technologies from one
country to another (ex. Pre-1996 US ban on
exporting technologies to Vietnam), and
general IP/TP management capacity and
resources.
License segmentation raises other questions
about equity, compliance and enforcement,
cultural and historical values, germplasm
origin, and product development resource
investment, to name only a few. Furthermore,
questions about the rights and values to be
exchanged between licensor and licensee are
profound and far-reaching. There is no clear
template readily available.
As mentioned above, this option may appear
the least appealing, at least in the short term,
because of the resources required to answer
all the questions and manage the issues of IP/
TP FTO. However, it has the appeal of being
the most effective in terms of a model for
capacity building among the licensees, a set
of skills that such licensees will undoubtedly
need in future negotiations, particularly if they
wish to export higher value food
biotechnology products.
Finally, this option is appealing in that instead
of creating a negative attitude, it builds bonds
of trust between the licensors and the licens-
ees. This is an important issue since it also al-
lows the transfer of know-how related to cer-
tain IP, including trade secrets, which could
be instrumental in the efficient development
of products for resource-poor farmers. In
implementing this strategy, the same bonds of
trust will hold licensor and licensee together
during future aspects of the development of
GoldenRice, which will empower future
negotiations between the parties and may ex-
tend to other technologies.
5.5.6 OPTION 6: Mix of all Options
(1 to 5)
While research and development plans are
made to optimize the product, re-design of
constructs and acquisition on TP is planned
to minimize IP and TP conflicts (OPTION 2);
selected FTO issues are removed through
public (or private) rescinding of rights by
selected holders of certain IP/TP rights
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(OPTION 3); this moral high ground is used
to leverage additional rights holders to either
rescind their claims (OPTION 3) or to reduce
their demands within the context of license
negotiations (OPTION 5). In the end all
remaining unrescinded IP/TP rights can be
either licensed (OPTION 5) or ignored
(OPTION 4).
This option contains components of each of
the above (except the first Option [inventing
around inventions]). It still requires significant
resource expenditures to document and
manage each IP/TP component. Furthermore,
many questions arise similar to those indicated
in Option 5.
As noted above, separating commercially
licensed activities from other activities
involving GoldenRice may establish
additional variants on each of these four
options. However, this document is directed
primarily toward obtaining access to
GoldenRice for resource-poor farmers/
consumers, not toward commercial licensing.
Considering each of these options, a strong
argument can be made to manage FTO in a
manner similar to the management of the
technological research and product
development that is making GoldenRice a
reality.
5.6 Practical Considerations on
Where the Final Product is
Developed
Sections 5.3 and 5.4 discussed the product
and process patents and the distinction
between IP and TP. This section will discuss
the practical implications of these differences
based on a hypothetical example.
Suppose an entity in Vietnam wishes to
develop GoldenRice for farmers in Vietnam
with further transfer to Pakistan. Vietnamese
and Pakistani farmers would be growing the
GoldenRice. Vietnam would also export the
GoldenRice to the Philippines. A rice
researcher in Vietnam, therefore, has
essentially three options for managing the IP
of GoldenRice, namely:
Option A: Re-making of GoldenRice in
Vietnam by producing entirely new
constructs
A rice researcher in Vietnam isolates the same
key carotenoid biosynthetic genes as used by
Potrykus and Beyer, remakes all of the gene
constructs and components of GoldenRice,
reassembles the same transformation vectors
and systems, and essentially produce her/his
own version of GoldenRice that is identical
to the PotrykusBeyer version.
• Currently, such a product would have 9
patents (or IP) impinging upon it in
Vietnam.
• The distribution of such re-made
GoldenRice to Pakistan would not pose
a problem since no patents on such a
product are issued in Pakistan.
• Export of the product to the Philippines
might require the license under 1 patent6 .
• If no TP from other sources is used then
the researcher would not have to seek
licensing agreements for TP rights.
Option B: Re-making of GoldenRice in
Vietnam by extracting the relevant genes
from the PotrykusBeyer GoldenRice
A rice researcher in Vietnam removes the key
carotenoid biosynthetic genes from the
PotrykusBeyer GoldenRice constructs and
re-clones these for the purpose of re-making
his/her own version of GoldenRice.
6 The patent issued in the Philippines does, technically speaking, not extend to the Potrykus/Beyer product because strictly
speaking it covers only a protoplast-based method of rice transformation.
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• Currently, such a re-made product would
have 9 patents (or IP) rights attached to it
in Vietnam.
• The distribution of such a re-made
GoldenRice to Pakistan would not pose
a problem since no applicable patents are
issued in Pakistan.
• Export of the product to the Philippines
might require the license for 1 patent.
• The most important obstacle, however,
would be the TP rights associated with the
PotrykusBeyer GoldenRice which
would still require an agreement from the
TP rights owners.
• In the future event that the Potrykus-Beyer
GoldenRice patents issue in Vietnam,
Pakistan, or in the Philippines, depending
on the specific issued claims, licenses
under that patent may also be required.
Option C: Acquire the Potrykus/Beyer
GoldenRice
A rice researcher in Vietnam, using traditional
breeding methods, crosses the PotrykusBeyer
transformed japonica GoldenRice with
selected indica rice varieties in order to transfer
the beta-carotene trait into more desirable
cultivars.
• The transfer of GoldenRice from ETH
Zurich to the entity in Vietnam would likely
be done under a MTA for the TP
embedded in the transferred material.
Such a MTA would dictate any limitations
on the TP which ETH Zurich would wish
to impose on the Vietnamese entity.
• Currently, that re-made product would
have 9 patents (or IP) rights impinging
upon it in Vietnam.
• The distribution of such re-made
GoldenRice to Pakistan would likely not
pose a problem since no patents on the
current Potrykus-Beyer version of
GoldenRice have issued in Pakistan.
• Export of the product to the Philippines
might require the license for 1 patent. The
Philippine entity, depending on the terms
of the MTA, may also be required to
negotiate a license with the TP owners.
If, under any of the three situations described
above, either the PotrykusBeyer
GoldenRice patent or other patents that are
applicable to GoldenRice and/or its
components or embodiments, are filed and
issued in Vietnam, the Philippines or Pakistan,
then the IP landscape significantly changes.
Monitoring of the IP landscape and newly
issued patents would be done by regular FTO
updates by the IP/TP manager.
6. Conclusions: Implementing IP/TP Management Systems
There are many challenges regarding FTO for
GoldenRice at both the country and
international levels because:
1. The technology is quite complex,
comprising of many sophisticated
components and processes.
2. There are many potential IP/TP owners/
assignees.
3. The range of potential producers/
consumers of GoldenRice is widely
varied.
4. There exists a rapidly evolving global IP
landscape.
5. TP rights in plant biotechnology, while not
as widely understood as IP rights, are very
broadly accepted and generally enforced
on a worldwide basis.
6. GoldenRice may have significant value
in the world commodity market.
The FTO issues for commercial activities and
for humanitarian activities are nearly identical,
although the solutions may vary.
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6.1 Major Options on the Management
of IP associated with
GoldenRice™
These FTO challenges can be understood by
reviewing some background information and
by studying several alternative options
forward. One immediate issue, for example,
concerns the appropriate type of license that
should be sought for resource-poor farmers/
consumers. This example also allows the
examination of some of the alternatives that
are available to those entities that wish to see
GoldenRice broadly distributed.
Note that no clear, legal, internationally
accepted definition of the term non-
commercial license exists. That term has
crept into discussions regarding
GoldenRice but it is not universally defined.
On the other hand, a commercial license
for IP rights is broadly accepted to mean a grant
of rights under the objects, designs, or
technologies claimed in the issued patent that
is being licensed. Such commercial licenses
often use the language of patent law, as
promulgated in many countries, by granting
a right to make, use, import, or sell. all
claimed products or processes. Increasingly,
the granting language in many commercial
biotech seed and/or plant licenses has been
expanded beyond mere patent law language
to include a broader grant under both the IP
and TP rights. This expanded language for
such licenses grants the licensee rights to
make, have made, use, have used, import,
export, sell or have sold all plants, plant parts
and all related products and processes....
under the defined technology. A
GoldenRice commercial license would
likely contain such expansive language. Any
other sort of license might or might not contain
such language.
The question then arises, Is a commercial
license the most appropriate way to deliver
GoldenRice to resource-poor farmers/
consumers in developing countries?, even if
granted royalty-free (which would be
equivalent to a donation free-of-charge). It is
not the purpose of this study to answer
questions regarding the particular licensing
language that the parties may prefer. However,
it is important to raise these questions so that
licensee and licensor can properly discuss
such issues.
Regardless of which option discussed above
or which scenario is chosen, there are a series
of tasks that should be completed in order to
adequately manage the IP/TP rights on any
GoldenRice product:
1. Complete and regularly update the present
FTO analysis.
2. Develop a scientific strategic plan (who
manages, what is to be done, which
biotech and germplasm components are
to be used, where is the research is to be
done, who is to do the research, what are
the timelines for completion) for finalizing
the current scientific initiative.
3. Draft and negotiate a strategic plan for
distribution (who manages, what must be
licensed, list of licensors/licensees,
acceptable terms, timelines) of the finished
product(s).
4. Complete a cost/benefit analysis for the
preferred options.
6.1.1 Complete and Regular Updates
to the FTO
This preliminary FTO analysis is based on a
thorough study of the scientific research (as
was documented to ISAAA) that has been
completed to date. However, because the
research and product development regarding
GoldenRice is continuing, and the IP
landscape is dynamic, an annual (at least)
update to the present FTO analysis may be
necessary.
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6.1.2 Strategic Science Plan
The development of a scientific strategic plan
(who manages, what is to be done, which
biotech and germplasm components are to be
used, where is the research to be done, who
is to do the research, what are the timelines
for completion) for finalizing the current
scientific initiative may be under way. Such a
plan would include an analysis of the
technological and IP/TT barriers that could
limit the successful scientific introduction of a
final product, either within developing
countries for the benefit of resource-poor
farmers/consumers or for commercial
purposes in any part of the world. Also, if and
when new biotech constructs and/or
transformation events are produced, such a
plan would allow the scientists, with a keen
eye toward the reduction of FTO barriers as
well as for the normal scientific purposes of
elegance and/or convenience, to re-design
components of GoldenRice.
The elimination of FTO barriers noted here
might include:
• Establishing authentic title to all
component parts and using those
components that are more freely available,
• Assuring that signatories to all germane
agreements (material transfer agreements,
licenses, sub-licenses, etc.) are empowered
to sign such documents,
• Documenting full compliance with all
germane agreements,
• Determining and documenting that all
inventors employment obligations vis-à-
vis all inventions are fulfilled,
• Establishing and maintaining an adequate
paper trail on all aspects of related
transactions, and
• Identifying and complying with
requirements that financial donors may
have imposed when research funding was
obtained.
6.1.3 Strategic Distribution Plan
The development of a strategic plan for
distribution (who manages, what must be
licensed, list of licensors/licensees, acceptable
terms, timelines) of the finished product(s) may,
likewise, be firmly underway. Determining
whether one or several entities should manage
the distribution process may be desirable to
achieve economies of scale and efficiencies
of operation.
Several alternatives for distribution could be:
• Release GoldenRice on a country-by-
country basis with each recipient country
obtaining all of the licenses that it will need
to benefit its rice growers, processors,
exporters/importers, and consumers. This
approach could be facilitated through a
consortium of research/development
institutions (such as those of the CGIAR).
• Distribute GoldenRice through a
consortium of regional countries.
• Identify and license a single country per
region and grant that country the right to
sub-license its GoldenRice.
Each of these approaches has merits and some
demerits. A distribution plan will help
determine which approach will have the
greatest impact and the highest cost/benefit
ratio. In any case, whatever licensing strategy
is pursued, practical issues regarding license
negotiations need to be reviewed and
answered:
• Which party within a country has both the
authority and the capacity to negotiate
with the licensors? Should there be only a
single licensee within each country?
Within each region? Why?
• Should licenses be sought on a country-
by-country basis, a regional basis, or in
some other manner?
• What is the correct value for a license?
How is such value determined? By whom?
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• Should any entity be denied a license?
Under what conditions? For how long?
• Should licenses be solely for domestic
production and consumption?
• Should export, if permitted at all, be
allowed only from one developing
country to other developing country?
Should exports to a developed country be
licensed in the same way that exports to a
developed country are treated?
• Should all licenses be commercial with
merely the terms varied? If so, varied
according to what criterion?
• Should all licensors treat every licensee the
same? Why? Why not?
• What are the alternatives to commercial
licenses?
• What defines a developing country as
compared to a developed country? Who
determines the distinction? Is such a
distinction permanent?
Raising these questions, of course, does not
resolve them. And even answering these
questions does not provide an exhaustive list
of answers to all the potential questions that
might arise if this option is followed.
This list of questions, however, can serve as a
checklist for various entities as they complete
the pragmatic working out of licensing
GoldenRice. For example, even though
there is likely to be more than one source of
GoldenRice licenses, all of the same
questions impinge upon the licensing
decisions. Likewise, even though
GoldenRice may be transferred under a
MTA to a developing country, the issues
embedded in the list above must be addressed.
Finally, whether the licensing of GoldenRice
is done one country (or entity) at a time when
each rice research/producing/consuming
country or organization is capable or is
licensed to a broker who in turn makes
additional sub-licenses to the appropriate
entities, the same concerns must be addressed.
The only significant difference may be one of
efficiencies and economies of scale. However,
these and related questions will have to be
approached and answered for any option
followed.
6.1.4 Cost/Benefit Analysis
Consideration of aspects of the distribution
plan ought to be coupled with a cost/benefit
analysis. Such an analysis considers what
constitutes appropriate license terms, sufficient
regulatory apparatus, and a predictable IP/TP
management framework. Which countries
have such institutions in place and what are
the costs of putting them in place are also
appropriate questions to ask.
Part of such an analysis would consider not
only the costs, but also the costs to whom. It
should also analyze the current relationship
that GoldenRice recipients have with
technological components and financial
donors as well as the potential relationships
created by distributing GoldenRice.
6.2 Outlook
It should be noted that the present study was
not intended to promulgate any particular
approach on how to overcome the IP and TP
challenges that impinge upon GoldenRice
nor to advocate a certain approach to IP
management. The objectives were two-fold:
a. review the IP and TP components
associated with  GoldenRice as
developed by Potrykus-Beyer (with
significant funding from the Rockefeller
Foundation)
b. develop and discuss possible alternative
strategies on how to overcome the IP and
TP constraints.
It will be for the developing countries which
wish to benefit from GoldenRice and for the
organizations whose mandate is to assist these
countries to make choices on the best options
to follow. The dominating consideration must
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be the impact of GoldenRice on the health
and well being of rice producing and
consuming populations. These and related
factors will condition the speed and
configuration of the eventual broad release of
GoldenRice.
Because a preliminary FTO analysis such as
this one and a related version done by a patent
attorney is dynamic, it is essential that all
strategic plans be developed in the light of an
extensive cost/benefit analysis and an
extensive list of likely options. In this way,
GoldenRice will deliver its benefits to both
resource-poor farmers and consumers in
developing countries and to commercial
farmers and related entities. It can become a
clear example of how the benefits of
genetically modified products can be
extended to both developing and developed
countries. Sound planning and resolution of
the IP/TT issues will contribute to a timely
release of this and future essential products
for the benefit of all people.
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Appendix A. List of Major Producing/Importing/Exporting Countries and Designated Patents Potentially




































































































































































































Appendix A continued. List of Major Producing/Importing/Exporting Countries and Designated Patents









































































































Appendix A continued. List of Major Producing/Importing/Exporting Countries and Designated Patents





















Appendix A continued. List of Major Producing/Importing/Exporting Countries and Designated Patents




















Appendix B. List of Abbreviations and Acronyms
aphIV hygromycin phosophotransferase (gene)
BoT Board of Trustees
CaMV Cauliflower mosaic virus
CGIAR Consultative Group on International Agricultural Research
crtI phytoene synthase (gene)
ETH Eidgenossische Technische Hochschule
FAO Food and Agriculture Organization
FTO Freedom-to-Operate
GATT General Agreement on Tariffs and Trade
Gt1 (rice) Endosperm-specific glutelin (gene)
HPLC High-performance liquid chromatography
IARC International Agricultural Research Center
IFPRI International Food Policy Research Institute
IIML Integrated Information Management Laboratory
IP Intellectual Property
IRRI International Rice Research Institute
ISAAA International Service for the Acquisition of Agri-biotech Applications
LB-RB Left-right border region (of Agrobacterium Ti plasmid)
lcy Lycopene cyclase (gene)
mpi Mannose phosphoisomerase
MTA Material Transfer Agreement
NARS National Agricultural Research Systems
NGO Non-Governmental Organization
nptII Neomycin phosphotransferase (gene)
NRC National Research Council (Canada)
PC Product Clearance
PCR Polymerase chain reaction
PCT Patent Cooperation Treaty (System)
pds Phytoene desaturase
PP Proprietary Property (comprising IP and TP)
psy Phytoene synthase (gene)
TP Technical Property
tp Transit peptide
TRIPs Trade-Related Intellectual Property
UPOV International Convention for the Protection of New Varieties of Plants
USAID United States Agency for International Development
USPTO United States Patent and Trademark Office
WTO World Trade Organization
zds (zeta)-carotene desaturase
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